<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Antioxidants (Basel)</journal-id>
<journal-id journal-id-type="iso-abbrev">Antioxidants (Basel)</journal-id>
<journal-id journal-id-type="publisher-id">antioxidants</journal-id>
<journal-title-group>
<journal-title>Antioxidants</journal-title>
</journal-title-group>
<issn pub-type="epub">2076-3921</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32423100</article-id>
<article-id pub-id-type="pmc">7278809</article-id>
<article-id pub-id-type="doi">10.3390/antiox9050425</article-id>
<article-id pub-id-type="publisher-id">antioxidants-09-00425</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Sobriety and Satiety: Is NAD+ the Answer?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0497-5572</contrib-id>
<name>
<surname>Braidy</surname>
<given-names>Nady</given-names>
</name>
<xref ref-type="aff" rid="af1-antioxidants-09-00425">1</xref>
<xref ref-type="corresp" rid="c1-antioxidants-09-00425">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Villalva</surname>
<given-names>Maria D.</given-names>
</name>
<xref ref-type="aff" rid="af1-antioxidants-09-00425">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Eeden</surname>
<given-names>Sam</given-names>
</name>
<xref ref-type="aff" rid="af2-antioxidants-09-00425">2</xref>
</contrib>
</contrib-group>
<aff id="af1-antioxidants-09-00425"><label>1</label>Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, NSW 2052, Australia; <email>m.villalva@unsw.edu.au</email></aff>
<aff id="af2-antioxidants-09-00425"><label>2</label>Centre for Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 4NS, UK; <email>s.vaneden@qmul.ac.uk</email></aff>
<author-notes>
<corresp id="c1-antioxidants-09-00425"><label>*</label>Correspondence: <email>n.braidy@unsw.edu.au</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>5</month>
<year>2020</year>
</pub-date>
<volume>9</volume>
<issue>5</issue>
<elocation-id>425</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>3</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Nicotinamide adenine dinucleotide (NAD+) is an essential pyridine nucleotide that has garnered considerable interest in the last century due to its critical role in cellular processes associated with energy production, cellular protection against stress and longevity. Research in NAD+ has been reinvigorated by recent findings that components of NAD+ metabolism and NAD-dependent enzymes can influence major signalling processes associated with the neurobiology of addiction. These studies implicate raising intracellular NAD+ levels as a potential target for managing and treating addictive behaviour and reducing cravings and withdrawal symptoms in patients with food addiction and/or substance abuse. Since clinical studies showing the use of NAD+ for the treatment of addiction are limited, this review provides literature evidence that NAD+ can influence the neurobiology of addiction and may have benefits as an anti-addiction intervention.</p>
</abstract>
<kwd-group>
<kwd>NAD+</kwd>
<kwd>cocaine</kwd>
<kwd>addiction</kwd>
<kwd>alcohol</kwd>
<kwd>cellular energetics</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-antioxidants-09-00425">
<title>1. Addiction: Today’s Most Common Modern Disease</title>
<p>Addiction represents the most common untreatable disorder in the 21st century. Addiction has a profound effect on individuals, their family and carers, and represents a major socio-economic burden on today’s healthcare system. Some epidemiological studies have suggested that addiction may be endemic in some populations [<xref ref-type="bibr" rid="B1-antioxidants-09-00425">1</xref>]. The most common forms of addiction are alcoholism and smoking, both of which have been associated with increased risk of developing age-related disorders which manifest in the cardiovascular and central nervous system [<xref ref-type="bibr" rid="B2-antioxidants-09-00425">2</xref>,<xref ref-type="bibr" rid="B3-antioxidants-09-00425">3</xref>,<xref ref-type="bibr" rid="B4-antioxidants-09-00425">4</xref>,<xref ref-type="bibr" rid="B5-antioxidants-09-00425">5</xref>]. Tobacco smoking is the most preventable cause of morbidity and mortality worldwide. It has been estimated that of the 38 million people in the United States of America alone who attempt to quit smoking, more than 85% relapse within the first few weeks following withdrawal interventions. Abstinent smokers who successfully withdraw in the first few months are susceptible to relapse after six months or even years later [<xref ref-type="bibr" rid="B6-antioxidants-09-00425">6</xref>]. Alcoholism is the third leading cause of death after cardiovascular disease and cancer and is associated with over 2.3 million deaths worldwide every year. Alcoholism is the ninth major contributor to global disease burden as measured by the disability-adjusted life years (DALYs) [<xref ref-type="bibr" rid="B2-antioxidants-09-00425">2</xref>,<xref ref-type="bibr" rid="B3-antioxidants-09-00425">3</xref>,<xref ref-type="bibr" rid="B4-antioxidants-09-00425">4</xref>,<xref ref-type="bibr" rid="B5-antioxidants-09-00425">5</xref>]. As with other forms of addiction, relapse occurs in response to exposure to environmental stimuli that are linked to the rewarding effects of the stimulant. Moreover, substance abuse (e.g., cocaine and heroin), internet addiction and excessive gambling are growing problems among the younger generation [<xref ref-type="bibr" rid="B7-antioxidants-09-00425">7</xref>].</p>
<p>Food addiction has been associated with obesity, a global complex health problem that is dependent on multidisciplinary treatment and various health practitioners including experts in mental health, medicine and surgery [<xref ref-type="bibr" rid="B1-antioxidants-09-00425">1</xref>]. Obesity has been associated with addictive behaviour that has a profound effect on morbidity and mortality leading to a reduction in the overall quality of life. The World Health Organization estimates that by the year 2030, over 57.8% of the world’s population will be obese. Obesity represents the second cause of death in the United States alone, affecting nearly 35 million people alone. Obesity has a negative effect on metabolic and endocrine processes that can lead to multiple organ disorders, malignant diseases such as cancers, mechanical impairments, surgical complications, and psychosocial deficits [<xref ref-type="bibr" rid="B8-antioxidants-09-00425">8</xref>,<xref ref-type="bibr" rid="B9-antioxidants-09-00425">9</xref>,<xref ref-type="bibr" rid="B10-antioxidants-09-00425">10</xref>,<xref ref-type="bibr" rid="B11-antioxidants-09-00425">11</xref>]. Obesity is also associated with genetic predisposition, impaired hormonal and metabolic processes, as well as confounding psychological and lifestyle factors [<xref ref-type="bibr" rid="B12-antioxidants-09-00425">12</xref>,<xref ref-type="bibr" rid="B13-antioxidants-09-00425">13</xref>,<xref ref-type="bibr" rid="B14-antioxidants-09-00425">14</xref>,<xref ref-type="bibr" rid="B15-antioxidants-09-00425">15</xref>]. This suggests that obesity is not a single disease, but rather a manifestation of several pathological, physiological and psychological processes leading to endocrine-metabolic dysfunction.</p>
<p>Substantial research into the pathobiology and mechanisms of addiction, and addiction therapy are yet to yield effective responses. The most successful addiction programs demonstrate a relapse-response rate of 56% in subjects [<xref ref-type="bibr" rid="B16-antioxidants-09-00425">16</xref>,<xref ref-type="bibr" rid="B17-antioxidants-09-00425">17</xref>,<xref ref-type="bibr" rid="B18-antioxidants-09-00425">18</xref>,<xref ref-type="bibr" rid="B19-antioxidants-09-00425">19</xref>,<xref ref-type="bibr" rid="B20-antioxidants-09-00425">20</xref>]. Given the importance of improving the prevention and successful treatment of addiction, there is a growing need to investigate new factors that may be associated with addictive behaviour. Various experimental approaches suggest that replenishment or augmentation of cellular levels of the essential pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) can provide ameliorative benefits and significantly lower relapse in addiction.</p>
</sec>
<sec id="sec2-antioxidants-09-00425">
<title>2. Neurobiology of Addiction</title>
<p>A wealth of evidence has identified several similarities between individuals who demonstrate addictive food behaviour and those that are diagnosed as addicted to substances. DiLeone et al. showed that individuals that are addicted to food describe similar processes (e.g., rewarding properties, withdrawal symptoms and overeating) to those addicted to drug and alcohol addicts [<xref ref-type="bibr" rid="B21-antioxidants-09-00425">21</xref>,<xref ref-type="bibr" rid="B22-antioxidants-09-00425">22</xref>]. Food in today’s contemporary society is rich in calories, saturated fats, sugars, synthetic additives (e.g., colours) and preservatives which are of low nutritional value and widely accessible. Compulsive over-consumption of foods rich in salt and additives or saturated with sugars and lots of calories has the greatest potential for addiction [<xref ref-type="bibr" rid="B23-antioxidants-09-00425">23</xref>]. These foods are termed ‘hyper palatable’, and can induce hedonistic behaviours and inhibit negative thoughts similar to substance abuse [<xref ref-type="bibr" rid="B24-antioxidants-09-00425">24</xref>,<xref ref-type="bibr" rid="B25-antioxidants-09-00425">25</xref>]. This can induce excessive preoccupation of food and periodic eating of large amounts of food within a very short time frame. These events may occur either once a day or once a week, leading to feelings of culpability, ignominy and depression, triggering further over-consumption of foods due to increased emotional stress [<xref ref-type="bibr" rid="B26-antioxidants-09-00425">26</xref>,<xref ref-type="bibr" rid="B27-antioxidants-09-00425">27</xref>]. Like substance abuse and sex addiction, ‘over-eating’ represents an in-effective mechanism to overcome negative thoughts or mediate ‘self-control’ [<xref ref-type="bibr" rid="B1-antioxidants-09-00425">1</xref>]. There are also various similarities between the molecular basis of food and drug addiction which are detailed below.</p>
<sec id="sec2dot1-antioxidants-09-00425">
<title>2.1. Hyper-Activation of the Glutaminergic System</title>
<p>Overactivation of the glutaminergic system has been shown to play an important role in substance abuse and obese conditions. In particular, it has been previously shown that treatment with N-methyl-D-aspartate receptor (NMDAR) antagonists can attenuate drug cue associations, and reduce cue-induced drug seeking and relapse-like behaviour [<xref ref-type="bibr" rid="B28-antioxidants-09-00425">28</xref>]. Moreover, intracerebroventricular and lateral hypothalamic injections of glutamate, or its excitatory amino acid agonists, kainic acid, AMPA, and N-methyl-D-aspartate (NMDA), enhance food appetite in murine models, while the mGluR5 receptor antagonist, (R,S)-2-chloro-5-hydroxyphenylglycine, suppresses appetite [<xref ref-type="bibr" rid="B29-antioxidants-09-00425">29</xref>]. However, alternative therapies are warranted since NMDAR antagonism can induce psycho-mimetic adverse effects (e.g., hallucinations, paranoia, cognitive deficits) due to NMDAR antagonism [<xref ref-type="bibr" rid="B30-antioxidants-09-00425">30</xref>]. </p>
</sec>
<sec id="sec2dot2-antioxidants-09-00425">
<title>2.2. Impaired Mitochondria Function</title>
<p>There is also substantial evidence indicating that brain energy homeostasis is perturbed in substance abuse and metabolic syndrome. This includes impairments in glucose metabolism, increased oxidative stress and reduced cellular respiration [<xref ref-type="bibr" rid="B31-antioxidants-09-00425">31</xref>,<xref ref-type="bibr" rid="B32-antioxidants-09-00425">32</xref>,<xref ref-type="bibr" rid="B33-antioxidants-09-00425">33</xref>,<xref ref-type="bibr" rid="B34-antioxidants-09-00425">34</xref>,<xref ref-type="bibr" rid="B35-antioxidants-09-00425">35</xref>]. However, very few studies are available in the literature that investigate mitochondrial changes in selected brain regions associated with the central reward pathway for substance abuse and food addiction. Recent studies have reported evidence of mitochondrial dysfunction in impaired motivation states such as depression, anxiety and stress [<xref ref-type="bibr" rid="B36-antioxidants-09-00425">36</xref>,<xref ref-type="bibr" rid="B37-antioxidants-09-00425">37</xref>]. For example, BCL-2, which regulates mitochondrial Ca<sup>2+</sup> homeostasis, has been associated with impairments in mood, and increased BCL-2 has been reported to stabilise mood [<xref ref-type="bibr" rid="B38-antioxidants-09-00425">38</xref>]. In addition, mutations in several mitochondrial genes have been associated with increased anxiety in several animal models [<xref ref-type="bibr" rid="B39-antioxidants-09-00425">39</xref>]. Transcriptomic profiling of the nucleus accumbens (NAc)—an important brain reward nucleus—identified enrichment in gene ontology of mitochondria-related transcripts following repeated cocaine exposure [<xref ref-type="bibr" rid="B40-antioxidants-09-00425">40</xref>]. Exposure to substances also impaired the activity and function of mitochondrial complex I, oxidative phosphorylation and ATP production, and mitochondrial membrane potential [<xref ref-type="bibr" rid="B31-antioxidants-09-00425">31</xref>]. </p>
<p>Furthermore, studies using functional magnetic resonance imaging (fMRI) reported increased activity in regions of the brain associated with motivation and reward when a sample of 48 women were drinking a chocolate milkshake or exposed to photographs of milkshake cups getting filled. Higher activity was observed in women with greater addiction scores, and less activation was reported in regions of the brain associated with inhibition of certain behaviours [<xref ref-type="bibr" rid="B25-antioxidants-09-00425">25</xref>,<xref ref-type="bibr" rid="B26-antioxidants-09-00425">26</xref>]. This suggests that these women were less able to control their behaviours when exposed to milkshakes as stimuli. Another study showed that food addiction was correlated with increased activation in the anterior cingulate cortex, medial orbitofrontal cortex and amygdala in response to eating. Greater activation was reported dorsolaterally in the prefrontal cortex and caudate nucleus, and less activation in the lateral orbitofrontal cortex, similar to drug addicts [<xref ref-type="bibr" rid="B25-antioxidants-09-00425">25</xref>,<xref ref-type="bibr" rid="B26-antioxidants-09-00425">26</xref>].</p>
</sec>
<sec id="sec2dot3-antioxidants-09-00425">
<title>2.3. Increased Neuroinflammation and Kynurenine Pathway Activation</title>
<p>Numerous studies have shown that neuroinflammation can induce depressive symptoms and increase the likelihood of developing addiction [<xref ref-type="bibr" rid="B41-antioxidants-09-00425">41</xref>,<xref ref-type="bibr" rid="B42-antioxidants-09-00425">42</xref>,<xref ref-type="bibr" rid="B43-antioxidants-09-00425">43</xref>,<xref ref-type="bibr" rid="B44-antioxidants-09-00425">44</xref>,<xref ref-type="bibr" rid="B45-antioxidants-09-00425">45</xref>,<xref ref-type="bibr" rid="B46-antioxidants-09-00425">46</xref>]. Activation of the kynurenine pathway (KP) of tryptophan (TRYP) degradation has been thought to play a major role in drug-related conditioned behaviours [<xref ref-type="bibr" rid="B47-antioxidants-09-00425">47</xref>]. Several products of the KP are neuroreactive. For example, quinolinic acid (QUIN) is an NMDAR agonist and its accumulation can lead to excitotoxicity and impaired glutaminergic transmission [<xref ref-type="bibr" rid="B48-antioxidants-09-00425">48</xref>,<xref ref-type="bibr" rid="B49-antioxidants-09-00425">49</xref>,<xref ref-type="bibr" rid="B50-antioxidants-09-00425">50</xref>]. Kynurenic acid (KYNA) is an NMDAR antagonist that exerts neuroprotective effects on the brain and can counteract the cytotoxic effects of QUIN [<xref ref-type="bibr" rid="B51-antioxidants-09-00425">51</xref>]. We and others have hypothesised that the QUIN/KYNA ratio represents a balance between neurodegeneration and neuroprotection in the brain which may be associated with immune activation [<xref ref-type="bibr" rid="B49-antioxidants-09-00425">49</xref>,<xref ref-type="bibr" rid="B52-antioxidants-09-00425">52</xref>,<xref ref-type="bibr" rid="B53-antioxidants-09-00425">53</xref>]. Inhibition of kynurenine-3-monooxygenase (KMO) by Ro61-8048 and its prodrug JM6 has been previously reported to induce a metabolic shift in the KP towards KYNA, thus reducing glutaminergic/NMDAR activity [<xref ref-type="bibr" rid="B47-antioxidants-09-00425">47</xref>]. KMO inhibition also abolished relapse-like alcohol drinking and alcohol and cocaine-seeking behaviours [<xref ref-type="bibr" rid="B47-antioxidants-09-00425">47</xref>]. However, given that nicotinamide adenine dinucleotide (NAD+) represents the final end product of the KP, it is unclear whether NAD+ levels can be effectively maintained when KMO is inhibited [<xref ref-type="bibr" rid="B54-antioxidants-09-00425">54</xref>]. </p>
</sec>
<sec id="sec2dot4-antioxidants-09-00425">
<title>2.4. Alterations in the Mesolimbic-Fronto Cortical Dopamine Pathway</title>
<p>The mesolimbic-fronto cortical dopamine (DA) system (composed of the mesolimbic and mesocortical DA systems) is an important pathway in brain reward [<xref ref-type="bibr" rid="B55-antioxidants-09-00425">55</xref>]. The neurotransmitter, DA, is a key component in the brain reward system. DA has been associated with both drug and food addiction. Alcohol consumption has been reported to directly stimulate DA release and increase DA levels [<xref ref-type="bibr" rid="B56-antioxidants-09-00425">56</xref>]. In addition, the behavioural rewards of nicotine are associated with DA release in the mesolimbic pathway [<xref ref-type="bibr" rid="B57-antioxidants-09-00425">57</xref>], and lesions in the mesolimbic DA pathway have been reported to lead to a reduction in self-administration of nicotine [<xref ref-type="bibr" rid="B55-antioxidants-09-00425">55</xref>]. Cannabinoid receptors have also been identified in regions of the brain associated with reward. The active component of cannabis, A’-tetrahydrocannabinol (A9-THC) has been shown to increase DA levels [<xref ref-type="bibr" rid="B58-antioxidants-09-00425">58</xref>]. </p>
<p>The brain reward system also plays a crucial role in food addiction, promoting adaptive behaviours (e.g., consuming palatable nutrients by linking them to pleasurable thoughts). Release of gastrointestinal (GI) hormones in response to nutrients in the GI tract, limit food intake through activation of the reward system by influencing motivational behaviour and its reward value [<xref ref-type="bibr" rid="B59-antioxidants-09-00425">59</xref>]. For instance, reduced GI production of the fat specific satiety factor oleoylethanolamide (OEA) can induce high-fat-diet induced obesity in mice [<xref ref-type="bibr" rid="B60-antioxidants-09-00425">60</xref>]. Negative feedback mechanisms also exist between the brain and the gut for sugars, consumption of which is dependent on taste and post-ingestive factors which have a direct effect on the brain reward system or mediating the production of endocrine factors that influence sucrose satiety and reward [<xref ref-type="bibr" rid="B61-antioxidants-09-00425">61</xref>].</p>
</sec>
<sec id="sec2dot5-antioxidants-09-00425">
<title>2.5. Dysregulation of Endocrine Factors</title>
<p>The neuropeptide and hormone oxytocin (OXT) has been thought to play a role in reward, stress, social and cognitive processes which are affected by addiction [<xref ref-type="bibr" rid="B62-antioxidants-09-00425">62</xref>]. OXT is a nonapeptide that is secreted by the brain from oxytocinergic neurons in the paraventricular and supraoptic nuclei of the hypothalamus [<xref ref-type="bibr" rid="B63-antioxidants-09-00425">63</xref>]. The association between OXT and addiction stems from similarities between behaviours reported in human addiction and social behaviours [<xref ref-type="bibr" rid="B64-antioxidants-09-00425">64</xref>]. Increased OXT levels following exogenous OXT via intranasal administration has been shown to boost trust, generosity and social recognition in humans without adverse effects [<xref ref-type="bibr" rid="B65-antioxidants-09-00425">65</xref>]. However, these effects are context or situation dependent. There is also evidence of a common neurobiology between social interaction and addition as demonstrated in prairie voles and rodents [<xref ref-type="bibr" rid="B66-antioxidants-09-00425">66</xref>]. Several preclinical studies have also shown that OXT can reverse the neuroadaptations occurring with chronic drug and alcohol use [<xref ref-type="bibr" rid="B67-antioxidants-09-00425">67</xref>]. </p>
<p>The liver is thought to be involved in the production of endocrine factors that influence addiction [<xref ref-type="bibr" rid="B68-antioxidants-09-00425">68</xref>]. Fibroblast growth factor 21 (FGF21) is a liver-derived hormone that has various physiological and pharmacological effects. FGF21 has been reported to normalise blood glucose levels in diabetic animals, promote fatty acid oxidation, prevent β cell dysfunction and reduce weight gain in the high-fat-diet induced mice models [<xref ref-type="bibr" rid="B69-antioxidants-09-00425">69</xref>,<xref ref-type="bibr" rid="B70-antioxidants-09-00425">70</xref>,<xref ref-type="bibr" rid="B71-antioxidants-09-00425">71</xref>,<xref ref-type="bibr" rid="B72-antioxidants-09-00425">72</xref>,<xref ref-type="bibr" rid="B73-antioxidants-09-00425">73</xref>,<xref ref-type="bibr" rid="B74-antioxidants-09-00425">74</xref>,<xref ref-type="bibr" rid="B75-antioxidants-09-00425">75</xref>]. FGF21 has also been reported to reduce sweet consumption in mice and humans whereas FGF21 knockout increases sugar consumption in murine models [<xref ref-type="bibr" rid="B76-antioxidants-09-00425">76</xref>,<xref ref-type="bibr" rid="B77-antioxidants-09-00425">77</xref>,<xref ref-type="bibr" rid="B78-antioxidants-09-00425">78</xref>]. Additionally, overproduction of FGF21 signals to the brain to regulate food intake, energy expenditure and fertility, and prevent age-related increases in weight gain and insulin resistance [<xref ref-type="bibr" rid="B68-antioxidants-09-00425">68</xref>,<xref ref-type="bibr" rid="B76-antioxidants-09-00425">76</xref>,<xref ref-type="bibr" rid="B77-antioxidants-09-00425">77</xref>,<xref ref-type="bibr" rid="B78-antioxidants-09-00425">78</xref>]. FGF21 gene therapy has been demonstrated to be a potential therapy for obesity and type 2 diabetes [<xref ref-type="bibr" rid="B79-antioxidants-09-00425">79</xref>]. Recently, FGF21 has also been reported to inhibit alcohol consumption in mice [<xref ref-type="bibr" rid="B80-antioxidants-09-00425">80</xref>]. The levels of FGF21 are increased in human plasma following acute alcohol consumption and sustained binge drinking [<xref ref-type="bibr" rid="B80-antioxidants-09-00425">80</xref>]. Taken together, these studies suggest that FGF21 is an endocrine inhibitor of alcohol and sugar consumption in humans.</p>
</sec>
<sec id="sec2dot6-antioxidants-09-00425">
<title>2.6. Importance of Circadian Rhythms</title>
<p>The underlying pathobiology of addiction and DA release may be regulated diurnally by interplay between circadian rhythms and metabolism. Circadian disruption has been reported to influence behavioural responses to substance abuse [<xref ref-type="bibr" rid="B81-antioxidants-09-00425">81</xref>,<xref ref-type="bibr" rid="B82-antioxidants-09-00425">82</xref>,<xref ref-type="bibr" rid="B83-antioxidants-09-00425">83</xref>,<xref ref-type="bibr" rid="B84-antioxidants-09-00425">84</xref>,<xref ref-type="bibr" rid="B85-antioxidants-09-00425">85</xref>]. For example, mutations in circadian genes in mice mediate differential locomotor sensitisation and conditioned preference to cocaine [<xref ref-type="bibr" rid="B86-antioxidants-09-00425">86</xref>]. It is thought that these circadian rhythms are controlled transcriptional-translational feedback loops and selected protein coding genes governed by the molecular clock. In particular, the main circadian transcription factors CLOCK and BMAL1 have been reported to couple with various intracellular metabolic signalling pathways [<xref ref-type="bibr" rid="B87-antioxidants-09-00425">87</xref>]. Circadian rhythms can regulate DA synthesis and release, which are dependent on the availability and activity of tyrosine hydroxylase (TH), whose transcriptional regulation is dependent on CLOCK/BMAL1 [<xref ref-type="bibr" rid="B88-antioxidants-09-00425">88</xref>].</p>
</sec>
<sec id="sec2dot7-antioxidants-09-00425">
<title>2.7. Role of Endogenous Opiates</title>
<p>Additionally, substance abuse and/or food have been shown to activate endogenous opiates, which represent a group of peptides that are produced in several organs and the brain and pituitary glands in particular [<xref ref-type="bibr" rid="B89-antioxidants-09-00425">89</xref>]. The endogenous opioid system influences the mesolimbic DA and the cortisol stress response, which are both implicated in addiction reward [<xref ref-type="bibr" rid="B90-antioxidants-09-00425">90</xref>]. The opioid antagonist naltrexone has been shown to inhibit the desire for sweet, salty and fatty foods, and alcohol and drugs [<xref ref-type="bibr" rid="B91-antioxidants-09-00425">91</xref>]. </p>
</sec>
</sec>
<sec id="sec3-antioxidants-09-00425">
<title>3. Historical Background of NAD+</title>
<p>Pellagra is a debilitating disorder caused by the deficiency of niacin and/or its precursor tryptophan. Symptoms of pellagra were first documented in 18th century by the Spanish doctor Gasper Casal, who described a disorder attributed to a diet deficient in meat [<xref ref-type="bibr" rid="B92-antioxidants-09-00425">92</xref>]. Pellagra was epidemic in malnourished regions of Europe and the southern states of the United States of America. Pellagra has been characterised as a ‘disease with four D’s’—dermatitis, diarrhoea, dementia and death [<xref ref-type="bibr" rid="B93-antioxidants-09-00425">93</xref>]. However, these classic symptoms rarely occur together or follow a predictable pattern, and are modified by environmental factors such as sun exposure, other concomitant vitamin deficiencies and disease progression [<xref ref-type="bibr" rid="B94-antioxidants-09-00425">94</xref>]. Excessive alcohol consumption represents a major risk factor for pellagra and chronic alcohol use can induce niacin deficiency [<xref ref-type="bibr" rid="B95-antioxidants-09-00425">95</xref>]. It has been reported that more than 100,000 Americans died from pellagra between 1907 and 1940. In 1914, Sir Joseph Goldberger linked pellagra to a nutrient deficiency due to a corn-rich diet. He suggested that dried yeast could be a cheap and effective therapeutic strategy to prevent pellagra [<xref ref-type="bibr" rid="B96-antioxidants-09-00425">96</xref>]. However, it was not until 1937 that Dr. Conrad Elvehjem demonstrated that nicotinic acid (NA) and nicotinamide (NAM) cured pellagra [<xref ref-type="bibr" rid="B97-antioxidants-09-00425">97</xref>]. </p>
<p>The metabolic significance of nicotinamide adenine dinucleotide (NAD+) was first identified by Sir Arthur Harden in 1906, who demonstrated that boiling and filtering yeast extract enhanced alcoholic fermentation in unboiled yeast extract. The active component was termed extract conferment or cozymase [<xref ref-type="bibr" rid="B98-antioxidants-09-00425">98</xref>]. In 1923, von Euler-Chelpin showed that cozymase was composed of a nucleoside sugar phosphate [<xref ref-type="bibr" rid="B99-antioxidants-09-00425">99</xref>]. Subsequently, the role of NAD+ as a hydrogen carrier in anaerobic and aerobic oxidation was identified by Sir Otto Warburg in 1933 [<xref ref-type="bibr" rid="B100-antioxidants-09-00425">100</xref>]. The pathways involved in NAD+ anabolism were fully characterised by Sir Arthur Kornberg, and the work of Priess and Handler in the 1940s and 1950s, respectively [<xref ref-type="bibr" rid="B101-antioxidants-09-00425">101</xref>]. The redox roles of NAD+ in glycolysis, the tricarboxylic acid cycle, oxidative metabolism and energy production were elucidated by several scientists including Krebs. The non-redox roles of NAD+ as a substrate for ADP-ribosylation reactions and histone deacetylase activities have been elucidated in the last few decades [<xref ref-type="bibr" rid="B101-antioxidants-09-00425">101</xref>]. Remarkably, maintaining NAD+ homeostasis is not only essential for the treatment of pellagra, but may also be associated with addiction, cardiovascular and neurodegenerative diseases and metabolic syndrome [<xref ref-type="bibr" rid="B54-antioxidants-09-00425">54</xref>]. </p>
<p>The significance of NAD+ in addictive disorders stems from the work of Dr. Paul O’ Hollaren (1961) who claimed to have successfully utilised IV NAD+ for the prevention and treatment of over 104 cases of addiction to alcohol and other drugs of abuse, including heroin, opium extract, morphine, dihydromorphine, meperidine, codeine, cocaine, amphetamines, barbiturates and tranquilisers [<xref ref-type="bibr" rid="B102-antioxidants-09-00425">102</xref>]. In his retrospective case series, IV NAD+ was administered at a dose of 500–1000 mg added to 300 cc normal saline daily for 4 days, twice per week for a month, followed by a maintenance dose twice per month until addiction was ameliorated, with limited toxic effects [<xref ref-type="bibr" rid="B102-antioxidants-09-00425">102</xref>]. NAD+ is likely to represent a cheap and useful holistic approach for the estimated millions of addicts worldwide, and may be an effective adjunct to psychotherapy, by ameliorating symptoms of physical addiction through a variety of mechanisms.</p>
</sec>
<sec id="sec4-antioxidants-09-00425">
<title>4. Summary of NAD+ Dependent Processes</title>
<p>There is a growing consensus that NAD+ levels decline at the cellular, tissue and organismal levels during ageing and progression of age-related degenerative diseases. NAD+ and its closely related phosphate NADP are cofactors in several anabolic and catabolic processes, such as fatty acid and cholesterol synthesis [<xref ref-type="bibr" rid="B103-antioxidants-09-00425">103</xref>]. NAD+ and NADP, and their reduced forms, NADH and NADPH, are important cofactors in more than 400 enzymatic reactions including dehydrogenases, hydroxylases and reductases [<xref ref-type="bibr" rid="B104-antioxidants-09-00425">104</xref>]. Recently, NAD+ has recently been reported to be an important reductant and hydride donor in biological oxidation of carbohydrate pathways [<xref ref-type="bibr" rid="B105-antioxidants-09-00425">105</xref>]. NAD+ is essential for the dehydrogenation of acetylaldehyde, which is essential for alcohol metabolism. Impaired oxidative phosphorylation in rat brain cortical slices following exposure to acetylaldehyde was attenuated by the addition of NAD+ [<xref ref-type="bibr" rid="B106-antioxidants-09-00425">106</xref>]. Although the reduced and phosphorylated forms can interconvert, they do not alter the levels of NAD+. The activity of several NAD-dependent enzymes or NAD+ ‘consumers’ are also affected by the decline in NAD+, influencing multiple processes and age-associated pathophysiologies. </p>
<sec id="sec4dot1-antioxidants-09-00425">
<title>4.1. Poly(ADP-Ribose)Polymerases (PARPs)</title>
<p>Poly(ADP-ribose)polymerases (PARPs) are a family of DNA ‘nick’ sensors that detect DNA strand breaks through its N-terminal zinc-finger domain [<xref ref-type="bibr" rid="B107-antioxidants-09-00425">107</xref>]. Poly(ADP)ribosylation breaks down NAD+ to NAM and an ADP-ribosyl product [<xref ref-type="bibr" rid="B108-antioxidants-09-00425">108</xref>]. Oxidative damage and neuroinflammation have been reported parallel to DNA damage. Therefore, NAD+ depletion due to hyperactivation of PARP1 and 2 in the nucleus may play an important role in the pathology of central nervous system (CNS) disorders [<xref ref-type="bibr" rid="B109-antioxidants-09-00425">109</xref>,<xref ref-type="bibr" rid="B110-antioxidants-09-00425">110</xref>,<xref ref-type="bibr" rid="B111-antioxidants-09-00425">111</xref>,<xref ref-type="bibr" rid="B112-antioxidants-09-00425">112</xref>,<xref ref-type="bibr" rid="B113-antioxidants-09-00425">113</xref>]. PARPs also regulate the tumour suppressor protein, p53. For instance, inhibition of poly(ADP)ribosylation and inactivation of p53 following treatment with etoposide was reported in PARP-deficient cell lines derived from Chinese hamster V79 cells [<xref ref-type="bibr" rid="B114-antioxidants-09-00425">114</xref>]. PARP has also been reported to activate DNA-dependent protein kinases which influence p53 activity via phosphorylation [<xref ref-type="bibr" rid="B115-antioxidants-09-00425">115</xref>]. Therefore, PARP activity is essential for the maintenance of DNA repair and genomic stability.</p>
</sec>
<sec id="sec4dot2-antioxidants-09-00425">
<title>4.2. CD38/NAD+ Glycohydrolase</title>
<p>CD38 is a major NADase in mammalian cells, and another NAD+-consuming enzyme [<xref ref-type="bibr" rid="B116-antioxidants-09-00425">116</xref>]. CD38 and CD157 hydrolyse NAD+ to generate ADP ribose (ADPR) and NAM. CD38 also produces the secondary messenger signalling molecule, cyclic-ADP-ribose (cADPR) which induces transient intracellular calcium waves. It has been estimated that about 100 molecules of NAD+ are necessary for hydrolysis to generate one molecular of cADPR. CD38 can also use the NAD+ precursors, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) to regulate intracellular NAD+ levels [<xref ref-type="bibr" rid="B117-antioxidants-09-00425">117</xref>]. It can also catalyse a base exchange between NADP and NA, generating nicotinic acid adenine dinucleotide phosphate (NAADP). CD38 has various immunomodulatory roles and increases in the levels of CD38 protein have been reported in several tissues over time, thus contributing to age-related NAD+ decline. CD38/cADPR also regulate oxytocin release, which is associated with social behaviours, and impaired CD38 function may induce several forms of neurological deficits [<xref ref-type="bibr" rid="B118-antioxidants-09-00425">118</xref>]. </p>
</sec>
<sec id="sec4dot3-antioxidants-09-00425">
<title>4.3. Sirtuins</title>
<p>Silent information regulators of gene transcription, or sirtuins, are a family of class III NAD+ dependent histone deacetylases enzymes that translate changes in NAD+ levels to the regulation of several proteins associated with cellular metabolism, cellular stress responses, circadian rhythms and endocrine functions. The deacetylation reaction involves acetyl group transfer to ADPR to form a novel compound called 2′-<italic>O</italic>-acetyl-ADPR or acetylated ADP-ribose [<xref ref-type="bibr" rid="B119-antioxidants-09-00425">119</xref>]. Cleavage of the glycosidic bonds in NAD+, leads to production of NAM as a by-product [<xref ref-type="bibr" rid="B120-antioxidants-09-00425">120</xref>]. Mammalian cells have seven classes of sirtuins (SIRT1–7) located in various cellular organelles, and control a variety of important biological processes [<xref ref-type="bibr" rid="B121-antioxidants-09-00425">121</xref>]. SIRT1 is a nuclear protein that is found mainly in the nucleus but can translocate to the cytoplasm, and is involved in promoting cellular longevity [<xref ref-type="bibr" rid="B122-antioxidants-09-00425">122</xref>] by influencing the acetylation/deacetylation status of several important transcription factors, including the metabolic regulator, peroxisome proliferator-activated receptor-γ (PPARγ), tumour suppressor protein (p53) and the cell growth linked FOXO forkhead family of transcription factors [<xref ref-type="bibr" rid="B123-antioxidants-09-00425">123</xref>]. SIRT2 is found in the cytoplasm but can also be found in the nucleus where it regulates gene expression and the cytoskeletal structure [<xref ref-type="bibr" rid="B124-antioxidants-09-00425">124</xref>]. SIRT3 [<xref ref-type="bibr" rid="B125-antioxidants-09-00425">125</xref>], SIRT4 [<xref ref-type="bibr" rid="B126-antioxidants-09-00425">126</xref>] and SIRT5 [<xref ref-type="bibr" rid="B127-antioxidants-09-00425">127</xref>] are found in mitochondrial compartments where they are involved in maintenance of mitochondrial redox status. SIRT6, another nuclear sirtuin, is involved in mediating an age-resistant phenotype [<xref ref-type="bibr" rid="B128-antioxidants-09-00425">128</xref>]. Finally, SIRT7 is found in the nucleolus of mammalian cells where it mediates growth and metabolism [<xref ref-type="bibr" rid="B129-antioxidants-09-00425">129</xref>]. Importantly, the beneficial effects of sirtuin activity are dependent on optimal NAD+ levels.</p>
</sec>
<sec id="sec4dot4-antioxidants-09-00425">
<title>4.4. Sterile Alpha and Toll/Interleukin-1 Receptor Motif-Containing 1 (SARM1)</title>
<p>Sterile alpha and Toll/interleukin-1 receptor motif-containing 1 (SARM1) is a recently discovered NAD+ hydrolase. Axonal degeneration is associated with NAD+ depletion and inhibition of SARM1 function delays axonal degeneration. The Toll/interleukin-1 receptor (TIR) domain of SARM1 is dependent on NAD+ for NAD+ hydrolase activity and enhances axonal degeneration [<xref ref-type="bibr" rid="B130-antioxidants-09-00425">130</xref>,<xref ref-type="bibr" rid="B131-antioxidants-09-00425">131</xref>,<xref ref-type="bibr" rid="B132-antioxidants-09-00425">132</xref>,<xref ref-type="bibr" rid="B133-antioxidants-09-00425">133</xref>,<xref ref-type="bibr" rid="B134-antioxidants-09-00425">134</xref>,<xref ref-type="bibr" rid="B135-antioxidants-09-00425">135</xref>].</p>
</sec>
<sec id="sec4dot5-antioxidants-09-00425">
<title>4.5. Interactions between NAD+ Consumers</title>
<p>We and others have previously demonstrated that the activity of PARP and SIRT1 is regulated by CD38, by potentially limiting the availability of NAD+ to its target enzymes [<xref ref-type="bibr" rid="B136-antioxidants-09-00425">136</xref>]. NAM, which is also produced by the catalytic activity of CD38, is also an endogenous inhibitor of SIRT1 and CD38. Therefore, CD38 represents an important regulator of SIRT1 activity and SIRT1 functions, including maintenance of cellular bioenergetics, obesity and senescence, mainly because it modulates the availability of NAD+ to the SIRT1 enzyme [<xref ref-type="bibr" rid="B137-antioxidants-09-00425">137</xref>]. There also exists a relationship between PARP1/2 and sirtuins, through their common substrate, NAD+. For example, PARP1/2 knockout enhances SIRT1 activity leading to increased mitochondrial function, fatty acid oxidation and protection against obesity [<xref ref-type="bibr" rid="B138-antioxidants-09-00425">138</xref>,<xref ref-type="bibr" rid="B139-antioxidants-09-00425">139</xref>]. However, while PARP1 knockout promotes NAD+ availability, PARP2 knockout promotes SIRT1 expression [<xref ref-type="bibr" rid="B140-antioxidants-09-00425">140</xref>,<xref ref-type="bibr" rid="B141-antioxidants-09-00425">141</xref>]. Therefore, chronic accumulation of oxidative stress and increased PARP activity plays a causal role in the decline in NAD+ and SIRT1 activity.</p>
</sec>
</sec>
<sec id="sec5-antioxidants-09-00425">
<title>5. Overview of NAD+ Biosynthetic Pathways</title>
<p>Given the importance of NAD+ in cellular bioenergetics and the need to maintain intracellular NAD+ pools in cells, several pathways are involved in the synthesis of NAD+. These include but may not be limited to: (1) de novo NAD+ synthesis from the amino acid TRYP via the KP; (2) NAD+ salvage pathway from vitamin B3 derivatives NA, NAM, NR and nicotinic acid riboside (NAR); and (3) major recycling pathway through NAM (<xref ref-type="fig" rid="antioxidants-09-00425-f001">Figure 1</xref>) (reviewed in [<xref ref-type="bibr" rid="B54-antioxidants-09-00425">54</xref>]). Evidence suggests that the entire intracellular NAD+ pool may be consumed several times a day [<xref ref-type="bibr" rid="B142-antioxidants-09-00425">142</xref>]. NAD+ anabolism is dependent on the availability of potential precursors, and not all of these precursors are bioequivalent [<xref ref-type="bibr" rid="B143-antioxidants-09-00425">143</xref>].</p>
<sec id="sec5dot1-antioxidants-09-00425">
<title>5.1. NAD+ from Tryptophan</title>
<p>TRYP is converted to NAD+ via an eight-step process known as the KP. The conversion of TRYP to NAD+ occurs when the substrate supply is greater than the enzymatic capacity of 2-amino-3-carboxymuconate semialdehyde (ACMSD), an enzyme required for the synthesis of the NMDAR antagonist and endogenous metal chelator, picolinic acid (PIC) [<xref ref-type="bibr" rid="B54-antioxidants-09-00425">54</xref>]. The NAD+ equivalence of 60 mg TRYP to 1 mg niacin may be partially explained by the fact that most of TRYP is used by the cell for protein synthesis. The daily recommend TRYP intake is 4 mg/kg body weight for adults [<xref ref-type="bibr" rid="B101-antioxidants-09-00425">101</xref>]. Studies have shown that the levels of NAM have little effect on the de novo biosynthesis rate of NAD+ from TRYP. Oral supplementation with TRYP at 15 g/day has been reported to induce some adverse effects including drowsiness and headache [<xref ref-type="bibr" rid="B144-antioxidants-09-00425">144</xref>]. Overconsumption of TRYP is capable of increasing the levels of QUIN which has been associated with neurodegenerative disorders, anxiety and seizures [<xref ref-type="bibr" rid="B48-antioxidants-09-00425">48</xref>]. Therefore, TRYP is unlikely to represent an ideal pharmaceutical source to raise NAD+ levels.</p>
</sec>
<sec id="sec5dot2-antioxidants-09-00425">
<title>5.2. NAD+ from Nicotinic Acid</title>
<p>NA is converted to nicotinic acid mononucleotide (NAMN) by the ATP-dependent enzyme nicotinic acid phosphoribosyl transferase (NAPRT) (EC 6.3.4.21) using PRPP as a co-substrate. As QUIN is converted to NAMN by the enzyme QPRT, the sequence of events leading to NAD+ production is identical to NAD+ from TRYP after NAMN formation [<xref ref-type="bibr" rid="B145-antioxidants-09-00425">145</xref>]. NAPRT appears to be expressed in several catabolic tissues including the colon, heart, kidney and liver [<xref ref-type="bibr" rid="B146-antioxidants-09-00425">146</xref>]. Adenylation of NAMN is dependent on the catalytic activity of NAD pyrophosphorylase or nicotinamide mononucleotide adenylyltransferase (NMNAT) (EC 2.7.7.1) in the presence of ATP to produce desamido NAD [<xref ref-type="bibr" rid="B147-antioxidants-09-00425">147</xref>,<xref ref-type="bibr" rid="B148-antioxidants-09-00425">148</xref>]. Three NMNAT isoforms are NMNAT-1 (nucleus), NMNAT-2 (Golgi complex) and NMNAT-3 (mitochondria) [<xref ref-type="bibr" rid="B149-antioxidants-09-00425">149</xref>]. This suggests an organelle-specific function for enzymes, and specific nuclear, mitochondrial and Golgi-specific NAD+ anabolic pathways. NMNAT-2 and -3 can also form NADH directly from reduced nicotinamide mononucleotide (NMN) [<xref ref-type="bibr" rid="B150-antioxidants-09-00425">150</xref>]. NMNAT activity (and predominantly NMNAT-1) is high and non-rate-limiting in catabolic tissue, but not in blood [<xref ref-type="bibr" rid="B151-antioxidants-09-00425">151</xref>].</p>
<p>The process involved in the synthesis of NAD+ from NA is known as the Priess–Handler process. NA has been shown to increase intracellular NAD+ levels in a kidney cell line [<xref ref-type="bibr" rid="B152-antioxidants-09-00425">152</xref>]. Oral supplementation of 1–3 g of NA daily lowers blood triglyceride levels and low-density lipoproteins (LDLs), and increases the levels of high-density lipoproteins (HDLs) [<xref ref-type="bibr" rid="B153-antioxidants-09-00425">153</xref>,<xref ref-type="bibr" rid="B154-antioxidants-09-00425">154</xref>]. Exogenous NA also increases intracellular NAD+ levels in brain cells [<xref ref-type="bibr" rid="B155-antioxidants-09-00425">155</xref>]. However, NA therapy induces significant skin flushing in most individuals, thus limiting its clinical use as an NAD+ precursor. A mild skin flush has been reported in patients exposed to doses as low as 50 mg oral NA [<xref ref-type="bibr" rid="B156-antioxidants-09-00425">156</xref>]. The lipid lowering effects and adverse effects of NA are thought to be mediated by interaction of NA to the cell surface of a G-protein coupled receptor known as HM74A or GPR109A, which enhances the conversion of the omega-6 metabolite arachidonic acid (AA) into prostaglandin E2, stimulating vasodilation of skin capillaries, causing unwanted skin flush [<xref ref-type="bibr" rid="B156-antioxidants-09-00425">156</xref>].</p>
</sec>
<sec id="sec5dot3-antioxidants-09-00425">
<title>5.3. NAD+ from Nicotinamide Recycling</title>
<p>Data in the literature suggest that half-lives of most enzymes involved in NAD+ consumption are 4–10 h [<xref ref-type="bibr" rid="B142-antioxidants-09-00425">142</xref>]. This suggests that 200–600 µmol/kg of NAM needs to be recycled back to NAD+ per day per tissue in rats. This is equivalent to consumption of 3 g of NAM several times a day in a 75 kg adult human [<xref ref-type="bibr" rid="B142-antioxidants-09-00425">142</xref>]. These levels are considerably lower than the recommended doses of NAM from diet (i.e., 1 lb tuna is required for 100 mg NAM, 1 lb beef generates 30 mg NAM while four cups of broccoli retain 4 mg NAM). Therefore, effective NAM recycling pathways are necessary to protect against NAD+ deficiency in humans. Recycling of NAM to NAD+ is dependent on the enzyme nicotinamide phosphoribosyl transferase (NAMPT) (EC 2.4.2.12) using PRPP as a co-substrate which converts NAM to NMN, and then to NAD+ by the action of NAD pyrophosphorylases in the presence of ATP [<xref ref-type="bibr" rid="B157-antioxidants-09-00425">157</xref>]. The rate of NAM recycling is highest in the liver and kidney, and lowest in blood [<xref ref-type="bibr" rid="B151-antioxidants-09-00425">151</xref>]. The recommended dose of NAM is 14–16 mg per day and is suggestive of a net loss not exceeding 0.5% total NAD+ per day to maintain NAD+ homeostasis. Considering that the intracellular NAD+ pools may be replaced up to four times per day, this reflects a total loss of 0.1–0.2% NAM per cycle [<xref ref-type="bibr" rid="B158-antioxidants-09-00425">158</xref>]. NAM is methylated by the enzyme nicotinamide N-methyltransferase (NNMT) (EC 2.1.1.1) to N-methylnicotinamide (MeNAM). MeNAM plays important roles in several metabolic and epigenetic processes and can influence neurodegeneration and ageing. Therefore, while supplementation with NAM can raise NAD+ and does not cause flushing, it is not considered an ideal supplement due to its enzyme inhibiting (e.g., PARPs, sirtuins, CD38) and methyl depleting potential.</p>
</sec>
<sec id="sec5dot4-antioxidants-09-00425">
<title>5.4. NAD+ from Nicotinamide Riboside and Nicotinic Acid Riboside</title>
<p>NR or NAR represent newly identified precursors that can be used to synthesise NAD+ via the NR kinase (NRK) (EC 2.7.1.173) pathway [<xref ref-type="bibr" rid="B159-antioxidants-09-00425">159</xref>]. Two NRK enzymes have been identified, NRK1 and NRK2, although, their exact physiological roles remain unclear. Dephosphorylation of NMN into NR, which is required to produce NAD+ in yeast, represents a crucial step for increasing intracellular NAD+ in mammalian cells [<xref ref-type="bibr" rid="B160-antioxidants-09-00425">160</xref>]. NR can also be catabolised into a ribosyl product and NAM via an NRK-independent pathway, which can then be further recycled to yield NAD+. Purine nucleoside phosphorylase (PNP) (EC 2.4.2.1) can convert NAR to NA, which is then converted to NAMN by the activity of NAPRT [<xref ref-type="bibr" rid="B161-antioxidants-09-00425">161</xref>]. NR appears to be safe and orally bioavailable in mice and humans with very few minor side effects reported [<xref ref-type="bibr" rid="B162-antioxidants-09-00425">162</xref>]. NR is currently a lead candidate in several preclinical and human clinical trials to evaluate whether it can be used for the treatment of age-related degenerative disorders [<xref ref-type="bibr" rid="B163-antioxidants-09-00425">163</xref>], given that NAD+ decline and/or increased NAD+ consumption may be a major risk factor in these debilitating disorders.</p>
</sec>
</sec>
<sec id="sec6-antioxidants-09-00425">
<title>6. NAD+ Metabolism: Cellular Energy, Secondary Messenger Signalling and Manipulation for Addiction</title>
<p>Given the global effects of NAD+ and SIRT1 on human physiology and function, NAD+ levels can influence anxiety, exploratory and depressive behaviour, and the brain reward system linked to addiction. NAD+ is likely to represent a molecular link between metabolism and psychiatric conditions [<xref ref-type="bibr" rid="B164-antioxidants-09-00425">164</xref>]. It has been well established that substance abuse and food addiction can impair metabolism, alter the cellular redox status, disrupt circadian rhythms and promote oxidative stress and neuroinflammation [<xref ref-type="bibr" rid="B165-antioxidants-09-00425">165</xref>]. NAD+ regulates intracellular calcium levels during DA release via increased CD38 activity, therefore reducing NAD+ availability [<xref ref-type="bibr" rid="B166-antioxidants-09-00425">166</xref>]. There is also evidence of a functional relationship between NAD+ and DA levels in the brain which is likely to be critical to brain function in physiological and pathological settings [<xref ref-type="bibr" rid="B101-antioxidants-09-00425">101</xref>,<xref ref-type="bibr" rid="B167-antioxidants-09-00425">167</xref>,<xref ref-type="bibr" rid="B168-antioxidants-09-00425">168</xref>]. Mechanisms by which NAD+ and its related processes can influence the neurobiology of addiction are described below.</p>
<sec id="sec6dot1-antioxidants-09-00425">
<title>6.1. SIRT1 Regulates Behavioural Responses Associated with Drug Addiction </title>
<p>The crucial role for SIRT1 and SIRT2 in modulating behavioural responses to cocaine and morphine in the NAc has been previously studied. One study reported increases in SIRT1 and SIRT2 expression in the mouse NAc following chronic cocaine administration, while only SIRT1 expression was increased following chronic morphine administration [<xref ref-type="bibr" rid="B169-antioxidants-09-00425">169</xref>]. Interestingly, cocaine and morphine had no effect on the expression of other sirtuin family members. Increased expression of SIRT1 and SIRT2 following exposure to drugs of abuse is partly attributed to the drug-induced transcription factor ΔFosB. In addition, the rewarding effects of cocaine and morphine were enhanced in mice following viral-mediated overexpression of SIRT1 or SIRT2 in the NAc and localised knockdown of SIRT1 in the NAc reduced drug reward [<xref ref-type="bibr" rid="B169-antioxidants-09-00425">169</xref>]. Therefore, sirtuins and SIRT1 and SIRT2, play key roles in mediating alterations in molecular and cellular plasticity induced by drugs of abuse in NAc, and may regulate behavioural adaptations following exposure to substance abuse.</p>
<p>The exact mechanisms by which SIRT1 can mediate cocaine-induced plasticity in NAc remain unclear. One study used chromatin immunoprecipitation after repeated cocaine (20 mg/kg) or saline injections, to characterise the SIRT1 binding genome-wide in mice NAc [<xref ref-type="bibr" rid="B170-antioxidants-09-00425">170</xref>]. The study reported three major findings. Firstly, chronic cocaine causes depletion of SIRT1 from most affected gene promoters and increases in H4K16ac (a deacetylation substrate of SIRT1). Secondly, cocaine-induced SIRT1 induction in the NAc promotes deacetylation and activation of FOXO3a and upregulation of various FOXO3a gene targets in other systems. Thirdly, overexpression of FOXO3a in NAc promotes cocaine place conditioning [<xref ref-type="bibr" rid="B170-antioxidants-09-00425">170</xref>]. Taken together, these findings suggest that SIRT1, an NAD-dependent enzyme, can influence molecular adaptations associated with cocaine addiction.</p>
</sec>
<sec id="sec6dot2-antioxidants-09-00425">
<title>6.2. NAD+ and SIRT1 Regulate Diurnal Rhythms Associated with Addiction Behaviour</title>
<p>The circadian transcription factors CLOCK and BMAL1 form heterodimers bind to enhancer E-box promoter elements to directly regulate gene transcription (<xref ref-type="fig" rid="antioxidants-09-00425-f002">Figure 2</xref>) [<xref ref-type="bibr" rid="B171-antioxidants-09-00425">171</xref>]. Owing to the location of E-box promoter elements to the transcriptional start site and the cAMP response element (CRE), direct transcriptional regulation of TH is mediated by CLOCK/BMAL1 [<xref ref-type="bibr" rid="B172-antioxidants-09-00425">172</xref>]. TH is the enzyme responsible for catalysing the synthesis of L-3,4-dihydroxyphenylalanine (L-DOPA) from the amino acid L-tyrosine, using molecular oxygen (O<sub>2</sub>), iron (Fe<sup>2+</sup>) and tetrahydrobiopterin as cofactors [<xref ref-type="bibr" rid="B173-antioxidants-09-00425">173</xref>]. L-DOPA is a precursor for DA, which is essential for the synthesis of the vital neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline) [<xref ref-type="bibr" rid="B173-antioxidants-09-00425">173</xref>]. TH enzyme represents the rate limiting step in the synthesis of catecholamines and is encoded by the TH gene. The TH gene is expressed in the CNS, peripheral sympathetic neurons and the adrenal medulla [<xref ref-type="bibr" rid="B173-antioxidants-09-00425">173</xref>]. </p>
<p>CLOCK is disrupted in substance abuse and mice exhibiting mutations in CLOCK are hyperdopaminergic and more susceptible to drug addiction [<xref ref-type="bibr" rid="B174-antioxidants-09-00425">174</xref>]. TH expression is upregulated in the mesolimbic DA system in mice harbouring the CLOCKΔ19 mutation, providing evidence of the regulatory role of CLOCK on the transcriptional activity of TH [<xref ref-type="bibr" rid="B175-antioxidants-09-00425">175</xref>]. Recent evidence suggests that the interaction between CLOCK and BMAL1 is regulated by the NAD-dependent histone deacetylase enzyme SIRT1 to repress CLOCK-mediated transcription [<xref ref-type="bibr" rid="B176-antioxidants-09-00425">176</xref>]. A recent study showed that CLOCK and NAD-dependent SIRT1 antagonise CREB-mediated transcription during the day, which is attenuated during the night, thus facilitating CREB-induced TH transcription at night. Impaired CLOCK in CLOCKΔ19 mice induces CREB-induced TH transcription during the day [<xref ref-type="bibr" rid="B176-antioxidants-09-00425">176</xref>]. </p>
<p>Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme in NAD+ biosynthesis pathway. NAMPT catalyses the conversion of NAM into NMN, which is subsequently converted to NAD+. One study recently demonstrated that NAMPT expression was significantly upregulated in the ventral tegmental area (VTA) of cocaine-conditioned mice [<xref ref-type="bibr" rid="B177-antioxidants-09-00425">177</xref>]. Intraperitoneal or intra-VTA injection of the NAMPT inhibitor FK866, attenuated cocaine reward, although the effect was repressed by increasing intra-VTA expression of NAMPT or supplementation with NMN [<xref ref-type="bibr" rid="B177-antioxidants-09-00425">177</xref>]. The levels of NAD+ and NMN, and SIRT1 expression were elevated in the VTA in cocaine-conditioned mice. However, the inhibitory effect of FK866 on cocaine reward was markedly reduced in SIRT1 midbrain conditional knockout mice [<xref ref-type="bibr" rid="B177-antioxidants-09-00425">177</xref>]. These results suggest that NAMPT-mediated NAD+ biosynthesis may influence cocaine behavioural effects via SIRT1. </p>
<p>NMN, an NAD+ precursor, also reduced CREB-mediated transcription, providing support for the importance of maintaining NAD+ levels as a key regulator of SIRT1-mediated transcriptional repression. Interestingly, the recycling of NAM to NMN is regulated by the CLOCK target gene, NAMPT [<xref ref-type="bibr" rid="B176-antioxidants-09-00425">176</xref>]. NAMPT and SIRT1 expression are highest during the diurnal phases and are opposite to the levels of NAD+ and SIRT1 protein, suggestive of NAD-dependent SIRT1 mediated repression of TH expression during the inactive phase. Daily changes in NAD+ levels regulate the CLOCK/BMAL1/SIRT1 heterodimer complexes [<xref ref-type="bibr" rid="B178-antioxidants-09-00425">178</xref>]. More specifically, CLOCK/SIRT1 preferentially binds to the TH promoter during the day when the levels of NAD+ are highest and the expression of TH is lowest. </p>
<p>Upregulation of SIRT1 and SIRT2 activities appears to be associated with increased excitability of NAc neurons following repeated cocaine exposure [<xref ref-type="bibr" rid="B179-antioxidants-09-00425">179</xref>]. This raises the possibility for the application of SIRT1 and SIRT2 inhibitors as potential agents to treat cocaine addiction.</p>
</sec>
<sec id="sec6dot3-antioxidants-09-00425">
<title>6.3. NAD+ Increases Adenosine Levels Which Counteract the Effects of Dopamine</title>
<p>The modulatory effects of DA are mediated by postsynaptic D1 and D2 receptors. The neuromodulator, adenosine, has been reported to attenuate DA signalling via modulation of adenosine A1 and A2A receptors. Thus adenosine receptors serve as endogenous ‘brakes’ on overactivated DA receptors and can attenuate drug-induced changes to neuronal function and cognitive disorders [<xref ref-type="bibr" rid="B180-antioxidants-09-00425">180</xref>]. Adenosine A1 receptors are found in the presynapsis where they compete with A2A receptors by receptor–receptor mediated interactions to inhibit glutamate release. Adenosine A1 and DA D1 receptors are expressed in the post synapsis on dynorphin-containing neurons while adenosine A2A receptors are expressed with dopamine D2 receptors in encephalin containing neurons [<xref ref-type="bibr" rid="B181-antioxidants-09-00425">181</xref>]. These receptors mediate opposing effects including allosteric receptor-receptor interactions and intracellular signalling cascades. Drugs of abuse have been reported to alter the expression of adenosine and DA receptors in the mesolimbic DA system, this limiting adenosine receptor activity in favour of increased DA stimulation and promoting addictive behaviour although the exact mechanism(s) remain unclear [<xref ref-type="bibr" rid="B182-antioxidants-09-00425">182</xref>].</p>
<p>Treatment with exogenous NAD+ has been shown to increase adenosine levels which are likely to activate adenosine receptors to counteract the degenerative effects of DA on neuronal cells [<xref ref-type="bibr" rid="B183-antioxidants-09-00425">183</xref>]. Endogenous adenosine levels have been reported to be in the nanomolar range [<xref ref-type="bibr" rid="B184-antioxidants-09-00425">184</xref>], and the potential beneficial effects of NAD+ in addiction may be partially mediated by increased adenosine levels and activation of adenosine receptors. A recent study showed that treatment with exogenous NAD+ increased intracellular adenosine levels in BV2 microglial cells which could enter cells through equilibrative nucleoside transporters [<xref ref-type="bibr" rid="B185-antioxidants-09-00425">185</xref>]. Increases in the intracellular adenylate pool can be converted to AMP by the catalytic activity of adenosine kinase, which increases intracellular ATP levels by enhancing AMP kinase (AMPK) activity and increasing ADP to promote mitochondrial ATP synthase activity [<xref ref-type="bibr" rid="B186-antioxidants-09-00425">186</xref>]. Therefore, extracellular NAD+ may have beneficial effects in addiction therapy through its degradation into adenosine, attenuation of DA receptor activity and the activities of adenosine kinase and AMPK.</p>
</sec>
<sec id="sec6dot4-antioxidants-09-00425">
<title>6.4. NAD+ and SIRT1 Regulate Monoamine Oxidase A</title>
<p>It has been reported that SIRT1 regulates anxiety and addictive behaviour, although the exact mechanism remains unclear [<xref ref-type="bibr" rid="B187-antioxidants-09-00425">187</xref>,<xref ref-type="bibr" rid="B188-antioxidants-09-00425">188</xref>,<xref ref-type="bibr" rid="B189-antioxidants-09-00425">189</xref>,<xref ref-type="bibr" rid="B190-antioxidants-09-00425">190</xref>,<xref ref-type="bibr" rid="B191-antioxidants-09-00425">191</xref>]. It has been recently reported that the NAD-dependent SIRT1 deacetylates the brain-specific transcription factor NHLH2 on lysine 49, which leads to increases in the activity of the monoamine oxidase A (MAO-A) promoter, thus activating MAO-transcription [<xref ref-type="bibr" rid="B190-antioxidants-09-00425">190</xref>]. Since MAO-A is responsible for the degradation of serotonin, increased MAO-A leads to reduced serotonin levels, thus increasing anxiety and depression. MAO-A inhibitors have been reported to normalise anxiety differences in murine models exhibiting altered brain SIRT1 levels. Genetic analysis of unbiased human cohorts reported that the role of sirtuins in regulating anxiety and behavioural disorders is conserved. These studies provide evidence for the role of sirtuins and the essential substrate NAD+ in mediating psychological effects on stress-response pathways [<xref ref-type="bibr" rid="B190-antioxidants-09-00425">190</xref>].</p>
</sec>
<sec id="sec6dot5-antioxidants-09-00425">
<title>6.5. NAD+ Regulates FGF21 and Oxytocin Signalling via SIRT1 and CD38</title>
<p>NAD-dependent SIRT1 plays an important role in regulating cellular energy homeostasis. In peripheral tissue, SIRT1 promotes the use of fat as a substrate [<xref ref-type="bibr" rid="B192-antioxidants-09-00425">192</xref>,<xref ref-type="bibr" rid="B193-antioxidants-09-00425">193</xref>,<xref ref-type="bibr" rid="B194-antioxidants-09-00425">194</xref>,<xref ref-type="bibr" rid="B195-antioxidants-09-00425">195</xref>,<xref ref-type="bibr" rid="B196-antioxidants-09-00425">196</xref>]. On the other hand, brain SIRT1 facilitates homeostatic feeding control enhancing hormone sensing. Recently, SIRT1 has been reported to be a regulator of macronutrient preferences and regulates macronutrient preference via FGF21-Nrf2-OXT signalling [<xref ref-type="bibr" rid="B197-antioxidants-09-00425">197</xref>]. FGF21 enhances OXT-mediated neuronal activation via ERK signalling and regulates OXT expression via AKT signalling. SIRT1 promotes FGF21 sensitivity in OXT neurons and enhances negative feedback processes that regulate simple sugar preference [<xref ref-type="bibr" rid="B197-antioxidants-09-00425">197</xref>]. </p>
<p>Importantly, obesity is associated with FGF21 resistance in peripheral tissue and the CNS due to reduced FGF21 receptor expression. FGF21 resistance in the CNS may play a critical role in obesity and metabolic syndrome [<xref ref-type="bibr" rid="B198-antioxidants-09-00425">198</xref>]. Hepatic SIRT1 is a key regulator of FGF21 transcription. Increased systemic SIRT1 activity due to increased NAD+ levels can enhance FGF21 signalling by raising the levels of FGF21 from the liver and increasing FGF21 signalling in OXT neurons [<xref ref-type="bibr" rid="B199-antioxidants-09-00425">199</xref>]. Interestingly, the circulating levels of OXT are reduced in obesity, and intranasal treatment with OXT led to a metabolic shift from using carbohydrates to fat [<xref ref-type="bibr" rid="B197-antioxidants-09-00425">197</xref>,<xref ref-type="bibr" rid="B200-antioxidants-09-00425">200</xref>]. Given the brain FGF21 stimulates OXT neurons and inhibits simple sugar preference, increasing FGF21 levels may also improve food selection and improve health and promote stress resistance. </p>
<p>Apart from SIRT1, NAD+ can also regulate OXT through CD38 [<xref ref-type="bibr" rid="B201-antioxidants-09-00425">201</xref>]. Effective social behaviour is dependent of optimal CD38 activity to regulate OXT secretion from the hypothalamus and pituitary [<xref ref-type="bibr" rid="B202-antioxidants-09-00425">202</xref>] (<xref ref-type="fig" rid="antioxidants-09-00425-f003">Figure 3</xref>). Social amnesia may be induced by reducing OXT secretion from the hypothalamus when CD38 activity is reduced due to gene manipulation or reduced availability of NAD+ [<xref ref-type="bibr" rid="B203-antioxidants-09-00425">203</xref>]. </p>
</sec>
<sec id="sec6dot6-antioxidants-09-00425">
<title>6.6. NAD+ and SIRT1 Regulate Drp1 and Mitochondrial Fission to Potentiate Drug Seeking</title>
<p>Impaired energy metabolism has been reported in the brains of subjects addicted to substances, and cocaine, although the exact mechanism remains unclear. It has been recently demonstrated that the dynamin-related protein-1 (Drp1), which mediated mitochondrial fission, is increased in the NAc following chronic cocaine exposure [<xref ref-type="bibr" rid="B204-antioxidants-09-00425">204</xref>]. A Drp1 inhibitor, Mdivi-1 inhibited cocaine seeking behaviour, and antagonised c-Fos induction and excitation onto D1 DA receptors [<xref ref-type="bibr" rid="B204-antioxidants-09-00425">204</xref>]. Since Drp1 expression and mitochondrial fission are regulated by SIRT1 [<xref ref-type="bibr" rid="B205-antioxidants-09-00425">205</xref>] and NAD+ (<xref ref-type="fig" rid="antioxidants-09-00425-f004">Figure 4</xref>) by deacetylating p53, reduced SIRT1 activity and NAD+ availability can alter brain energy homeostasis affecting behavioural and cellular plasticity during addiction. </p>
</sec>
</sec>
<sec id="sec7-antioxidants-09-00425">
<title>7. Is There Room for NAD+ in Addiction Therapy?</title>
<p>While NAD+ precursors (e.g., NAM, NMN and NR) have been shown to increase NAD+ levels after treatment, IV NAD+ remains the most direct method of raising NAD+ levels, although it is yet to gain U.S. Food and Drug Administration (FDA) approval. While data from experimental studies are limited, significant clinical benefit of IV NAD+ infusion in alcohol and opioid withdrawal has been previously reported [<xref ref-type="bibr" rid="B102-antioxidants-09-00425">102</xref>]. These authors found significant improvements in the removal of cravings and withdrawal symptoms. The benefits of NAD+ are likely to be extended to improving emotional disorders in patients with psychological disorders. Whilst there has been growing enthusiasm for the benefits of IV NAD+ therapy, the pharmacokinetics and pharmacodynamics of IV NAD+ remain nascent in the current literature. </p>
<p>A recent study documented changes in levels of NAD+ and key metabolites in the NAD+ metabolome (henceforth the NADome) in both plasma and urine over 8 h using a typical clinical dosing regimen of 750 mg NAD+ administered IV over a 6 h period [<xref ref-type="bibr" rid="B206-antioxidants-09-00425">206</xref>]. The study was the first to report that: (a) the level of NAD+ remained constant in the plasma for at least the first 2 h when administered at a flow rate of 3 μmole/min; (b) increases in the levels of metabolic bi-products analysed were consistent with the activity of NAD+ consumers (e.g., PARPs, CD38 and sirtuins); and (c) by-products of NAD+ metabolism and unbound NAD+ itself can be excreted in urine [<xref ref-type="bibr" rid="B206-antioxidants-09-00425">206</xref>]. However, further research is necessary to fully understand the complex metabolic fate of NAD+ following treatment.</p>
<p>Importantly, no adverse effect was reported following IV NAD+ infusion when administered at an appropriate rate [<xref ref-type="bibr" rid="B102-antioxidants-09-00425">102</xref>,<xref ref-type="bibr" rid="B206-antioxidants-09-00425">206</xref>]. However, reduced plasma activities of enzymes associated with hepatic stress such as the intrahepatic LD and AST and the post-hepatic (bile duct) enzyme GGT suggest that NAD+ is essential for the maintenance of structural and functional integrity of both intra-hepatic and post-hepatic tissue. Increases in bilirubin, a red cell degradation product, after 8 h may be indicative of a minor increase in red cell turnover, possibly due to infusion-induced haemolysis, or reduced heme metabolism. Since these increases are in a low magnitude of change, it was not considered to be of clinical relevance [<xref ref-type="bibr" rid="B206-antioxidants-09-00425">206</xref>]. IV NAD+ therapy may provide significant improvement in addictive disorders likely due to increased NAD+ availability. Further longitudinal and follow-up studies are necessary to cement the role of IV NAD+ in addiction therapy. In addition, the effect of oral administration of the NAD+ precursors, NMN and NR, as potential therapeutic agents for raising NAD+ and improving addictive symptoms warrants further clinical investigation. </p>
</sec>
<sec id="sec8-antioxidants-09-00425" sec-type="conclusions">
<title>8. Conclusions </title>
<p>The central role of NAD+ in the maintenance and regulation of cellular bioenergetics, and modulation of numerous secondary messenger signalling pathways suggest that NAD+ is essential for promoting cellular regeneration and repair in neuropsychiatric conditions such as addiction, Alzheimer’s disease and other neurodegenerative dementias. A growing body of evidence suggests that NAD+ levels decline with age and an imbalance in NAD+ anabolism and NAD+ consumption can lead to a significant derailment of fundamental molecular processes leading to accelerated degeneration and ageing [<xref ref-type="bibr" rid="B163-antioxidants-09-00425">163</xref>,<xref ref-type="bibr" rid="B164-antioxidants-09-00425">164</xref>,<xref ref-type="bibr" rid="B207-antioxidants-09-00425">207</xref>]. This review attempts to provide renewed insight into current knowledge of the NADome, and mechanisms by which NAD+ can interact with various processes in cells and tissues to attenuate addictive behaviour and reduce the addictive phenotype in the clinic. If NAD+ anabolism is impaired and/or if NAD+ consumption is increased during addiction, this is likely to reduce intracellular NAD+ pools which contribute to functional decline. NAD+ consumers such as PARPs, CD38, sirtuins and the more recently identified SARM1, may be affected not only in the brain but in other cells and tissues leading to a loss in NAD+ homeostasis that plays a contributory, if not causal, role in deficits in basic physiological processes associated with the neurobiology of addiction. </p>
<p>For several decades, IV NAD+ has been used as a holistic ‘underground’ approach for the treatment of various forms of addiction. IV NAD+ showed complete withdrawal of addictive drugs without subjects experiencing ‘agony of withdrawal’ symptoms [<xref ref-type="bibr" rid="B102-antioxidants-09-00425">102</xref>,<xref ref-type="bibr" rid="B206-antioxidants-09-00425">206</xref>]. It also provides a cheap and direct means for physicians to treat addiction without the necessity of using synthetic therapeutic agents that are more costly, pose greater risk of adverse effects and induce addiction or regimens that require ‘trafficking’ of addictive drugs for gradual withdrawal. However, it should be clarified that the use of NAD+ does not provide allowance for continued use of addicted drugs. Rather, NAD+ therapy is aimed at improving ‘productive ageing’ by restoring health processes, removing cravings and withdrawal symptoms and assisting in abstinence. Emerging studies using IV NAD+ in addiction set the stage for deeper investigations into the mechanisms by which addiction is sensitive to NAD+ status, and how it can improve, if not attenuate, addiction in the clinic. </p>
<p>Apart from the historical benefits of niacin and IV NAD+ in addiction therapy, the identification of NR, NAR and NMN as NAD+ precursors provide ‘newer’ alternatives for raising NAD+ levels and to possibly alleviate biochemical processes associated with addiction. These NAD+ precursors have already demonstrated protective effects in several animal models of disease including neurodegenerative disorders, cardiovascular disease, metabolic syndrome, cancer and ageing [<xref ref-type="bibr" rid="B54-antioxidants-09-00425">54</xref>,<xref ref-type="bibr" rid="B163-antioxidants-09-00425">163</xref>]. Given recent advances in quantifying the NADome in various biological specimens using specific biosensors and mass spectrometry techniques [<xref ref-type="bibr" rid="B208-antioxidants-09-00425">208</xref>], we are at an exciting time when we can evaluate the importance of NAD+ metabolism not only for prevention and management of ageing and age-related disorders, but in addictive behaviour as well.</p>
</sec>
</body>
<back>
<notes>
<title>Author Contributions</title>
<p>Conceptualization N.B. and S.v.E.—original draft preparation, N.B.; writing—review and editing, N.B., M.D.V. and S.v.E.; supervision, N.B. All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>This research received no external funding.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-antioxidants-09-00425">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimitrijević</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Popović</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sabljak</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Škodrić-Trifunović</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dimitrijević</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Food addiction-diagnosis and treatment</article-title>
<source/>Psychiatr. Danub.
          <year>2015</year>
<volume>27</volume>
<fpage>101</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="pmid">25751444</pub-id>
</element-citation>
</ref>
<ref id="B2-antioxidants-09-00425">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Axley</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Singal</surname>
<given-names>A.K.</given-names>
</name>
</person-group>
<article-title>Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease</article-title>
<source/>Clin. Liver Dis.
          <year>2019</year>
<volume>23</volume>
<fpage>39</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/j.cld.2018.09.011</pub-id>
<pub-id pub-id-type="pmid">30454831</pub-id>
</element-citation>
</ref>
<ref id="B3-antioxidants-09-00425">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fama</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hardcastle</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sassoon</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Pfefferbaum</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>E.V.</given-names>
</name>
<name>
<surname>Zahr</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Le Berre</surname>
<given-names>A.-P.</given-names>
</name>
</person-group>
<article-title>Neurological, nutritional and alcohol consumption factors underlie cognitive and motor deficits in chronic alcoholism</article-title>
<source/>Addict. Boil.
          <year>2019</year>
<volume>24</volume>
<fpage>290</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="doi">10.1111/adb.12584</pub-id>
<pub-id pub-id-type="pmid">29243370</pub-id>
</element-citation>
</ref>
<ref id="B4-antioxidants-09-00425">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ouellette</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tenbrink</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Gier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mitten</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Steinberger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Riley</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sutliffe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Alcoholism in elderly patients: Characteristics of patients and impact on the emergency department</article-title>
<source/>Am. J. Emerg. Med.
          <year>2019</year>
<volume>37</volume>
<fpage>776</fpage>
<lpage>777</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajem.2018.08.061</pub-id>
<pub-id pub-id-type="pmid">30170930</pub-id>
</element-citation>
</ref>
<ref id="B5-antioxidants-09-00425">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pucci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Bonaventura</surname>
<given-names>M.V.M.</given-names>
</name>
<name>
<surname>Wille-Bille</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fernández</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Maccarrone</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pautassi</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Cifani</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>D’Addario</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Environmental stressors and alcoholism development: Focus on molecular targets and their epigenetic regulation</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2019</year>
<volume>106</volume>
<fpage>165</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2018.07.004</pub-id>
<pub-id pub-id-type="pmid">30017749</pub-id>
</element-citation>
</ref>
<ref id="B6-antioxidants-09-00425">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santoro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tomino</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Prinzi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lamonaca</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cardaci</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Tobacco Smoking: Risk to Develop Addiction, Chronic Obstructive Pulmonary Disease, and Lung Cancer</article-title>
<source/>Recent Pat. Anti-Cancer Drug Discov.
          <year>2019</year>
<volume>14</volume>
<fpage>39</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.2174/1574892814666190102122848</pub-id>
</element-citation>
</ref>
<ref id="B7-antioxidants-09-00425">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jamir</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Duggal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nehra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Grover</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Epidemiology of technology addiction among school students in rural India</article-title>
<source/>Asian J. Psychiatry
          <year>2019</year>
<volume>40</volume>
<fpage>30</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajp.2019.01.009</pub-id>
</element-citation>
</ref>
<ref id="B8-antioxidants-09-00425">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armoon</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Karimy</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Epidemiology of childhood overweight, obesity and their related factors in a sample of preschool children from Central Iran</article-title>
<source/>BMC Pediatr.
          <year>2019</year>
<volume>19</volume>
<elocation-id>159</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12887-019-1540-5</pub-id>
<pub-id pub-id-type="pmid">31109318</pub-id>
</element-citation>
</ref>
<ref id="B9-antioxidants-09-00425">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bluher</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Obesity: Global epidemiology and pathogenesis</article-title>
<source/>Nat. Rev. Endocrinol.
          <year>2019</year>
<volume>15</volume>
<fpage>288</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.1038/s41574-019-0176-8</pub-id>
<pub-id pub-id-type="pmid">30814686</pub-id>
</element-citation>
</ref>
<ref id="B10-antioxidants-09-00425">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chooi</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Magkos</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>The epidemiology of obesity</article-title>
<source/>Metabolism
          <year>2019</year>
<volume>92</volume>
<fpage>6</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1016/j.metabol.2018.09.005</pub-id>
<pub-id pub-id-type="pmid">30253139</pub-id>
</element-citation>
</ref>
<ref id="B11-antioxidants-09-00425">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nansseu</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Noubiap</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Bigna</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Epidemiology of Overweight and Obesity in Adults Living in Cameroon: A Systematic Review and Meta-Analysis</article-title>
<source/>Obesity
          <year>2019</year>
<volume>27</volume>
<fpage>1682</fpage>
<lpage>1692</lpage>
<pub-id pub-id-type="doi">10.1002/oby.22566</pub-id>
<pub-id pub-id-type="pmid">31411372</pub-id>
</element-citation>
</ref>
<ref id="B12-antioxidants-09-00425">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giusti</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>[Obesity: Epidemiology, socio-political implications and conventional management]</article-title>
<source/>Ther. Umsch.
          <year>2019</year>
<volume>76</volume>
<fpage>117</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1024/0040-5930/a001071</pub-id>
<pub-id pub-id-type="pmid">31498046</pub-id>
</element-citation>
</ref>
<ref id="B13-antioxidants-09-00425">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imam</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Coleman</surname>
<given-names>K.J.</given-names>
</name>
</person-group>
<article-title>Obesity and Mortality in End-Stage Renal Disease. Is It Time to Reverse the “Reverse Epidemiology”-at Least in Peritoneal Dialysis?</article-title>
<source/>J. Ren. Nutr.
          <year>2019</year>
<volume>29</volume>
<fpage>269</fpage>
<lpage>275</lpage>
<pub-id pub-id-type="doi">10.1053/j.jrn.2018.09.005</pub-id>
<pub-id pub-id-type="pmid">30448394</pub-id>
</element-citation>
</ref>
<ref id="B14-antioxidants-09-00425">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>So</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Impact of dietary protein intake and obesity on lean mass in middle-aged individuals after a 12-year follow-up: The Korean Genome and Epidemiology Study (KoGES)</article-title>
<source/>Br. J. Nutr.
          <year>2019</year>
<volume>122</volume>
<fpage>322</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="doi">10.1017/S000711451900117X</pub-id>
<pub-id pub-id-type="pmid">31177993</pub-id>
</element-citation>
</ref>
<ref id="B15-antioxidants-09-00425">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vyas</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lambiase</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Centre</surname>
<given-names>S.B.H.B.H.</given-names>
</name>
</person-group>
<article-title>Obesity and Atrial Fibrillation: Epidemiology, Pathophysiology and Novel Therapeutic Opportunities</article-title>
<source/>Arrhythmia Electrophysiol. Rev.
          <year>2019</year>
<volume>8</volume>
<fpage>28</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.15420/aer.2018.76.2</pub-id>
</element-citation>
</ref>
<ref id="B16-antioxidants-09-00425">
<label>16.</label>
<element-citation publication-type="gov">
<person-group person-group-type="author">
<name>
<surname>Guenzel</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>McChargue</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Addiction Relapse Prevention</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK551500/">https://www.ncbi.nlm.nih.gov/books/NBK551500/</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-12-08">(accessed on 8 December 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B17-antioxidants-09-00425">
<label>17.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Heinz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mir</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grüsser</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grace</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wrase</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Alcohol Craving and Relapse Prediction: Imaging Studies</article-title>
<source/>Advances in the Neuroscience of Addiction
          <edition>2nd ed.</edition>
<person-group person-group-type="editor">
<name>
<surname>Kuhn</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Koob</surname>
<given-names>G.F.</given-names>
</name>
</person-group>
<publisher-name>CRC Press</publisher-name>
<publisher-loc>Boca Raton, FL, USA</publisher-loc>
<year>2010</year>
</element-citation>
</ref>
<ref id="B18-antioxidants-09-00425">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marshall</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Albery</surname>
<given-names>I.P.</given-names>
</name>
<name>
<surname>Frings</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Who stays in addiction treatment groups? Anxiety and avoidant attachment styles predict treatment retention and relapse</article-title>
<source/>Clin. Psychol. Psychother.
          <year>2018</year>
<volume>25</volume>
<fpage>525</fpage>
<lpage>531</lpage>
<pub-id pub-id-type="doi">10.1002/cpp.2187</pub-id>
<pub-id pub-id-type="pmid">29520879</pub-id>
</element-citation>
</ref>
<ref id="B19-antioxidants-09-00425">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mcgonigle</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Paterson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Reed</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Nestor</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nash</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ersche</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Flechais</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Newbould</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description</article-title>
<source/>J. Psychopharmacol.
          <year>2017</year>
<volume>31</volume>
<fpage>3</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1177/0269881116668592</pub-id>
<pub-id pub-id-type="pmid">27703042</pub-id>
</element-citation>
</ref>
<ref id="B20-antioxidants-09-00425">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vo</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Westwood</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lezama</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fishman</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Relapse prevention medications in community treatment for young adults with opioid addiction</article-title>
<source/>Subst. Abus.
          <year>2016</year>
<volume>37</volume>
<fpage>392</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="doi">10.1080/08897077.2016.1143435</pub-id>
<pub-id pub-id-type="pmid">26820059</pub-id>
</element-citation>
</ref>
<ref id="B21-antioxidants-09-00425">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DiLeone</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Neuroscience gets nutrition</article-title>
<source/>Nat. Neurosci.
          <year>2011</year>
<volume>14</volume>
<fpage>271</fpage>
<lpage>272</lpage>
<pub-id pub-id-type="doi">10.1038/nn0311-271</pub-id>
<pub-id pub-id-type="pmid">21346742</pub-id>
</element-citation>
</ref>
<ref id="B22-antioxidants-09-00425">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gearhardt</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Grilo</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Dileone</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Brownell</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Potenza</surname>
<given-names>M.N.</given-names>
</name>
</person-group>
<article-title>Can food be addictive? Public health and policy implications</article-title>
<source/>Addiction
          <year>2011</year>
<volume>106</volume>
<fpage>1208</fpage>
<lpage>1212</lpage>
<pub-id pub-id-type="doi">10.1111/j.1360-0443.2010.03301.x</pub-id>
<pub-id pub-id-type="pmid">21635588</pub-id>
</element-citation>
</ref>
<ref id="B23-antioxidants-09-00425">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulte</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Avena</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Gearhardt</surname>
<given-names>A.N.</given-names>
</name>
</person-group>
<article-title>Which foods may be addictive? The roles of processing, fat content, and glycemic load</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0117959</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0117959</pub-id>
<pub-id pub-id-type="pmid">25692302</pub-id>
</element-citation>
</ref>
<ref id="B24-antioxidants-09-00425">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gearhardt</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Brownell</surname>
<given-names>K.D.</given-names>
</name>
</person-group>
<article-title>Can food and addiction change the game?</article-title>
<source/>Biol. Psychiatry
          <year>2013</year>
<volume>73</volume>
<fpage>802</fpage>
<lpage>803</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2012.07.024</pub-id>
<pub-id pub-id-type="pmid">22877921</pub-id>
</element-citation>
</ref>
<ref id="B25-antioxidants-09-00425">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gearhardt</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Corbin</surname>
<given-names>W.R.</given-names>
</name>
<name>
<surname>Brownell</surname>
<given-names>K.D.</given-names>
</name>
</person-group>
<article-title>Food addiction: An examination of the diagnostic criteria for dependence</article-title>
<source/>J. Addict. Med.
          <year>2009</year>
<volume>3</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1097/ADM.0b013e318193c993</pub-id>
<pub-id pub-id-type="pmid">21768996</pub-id>
</element-citation>
</ref>
<ref id="B26-antioxidants-09-00425">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gearhardt</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Corbin</surname>
<given-names>W.R.</given-names>
</name>
</person-group>
<article-title>The role of food addiction in clinical research</article-title>
<source/>Curr. Pharm. Des.
          <year>2011</year>
<volume>17</volume>
<fpage>1140</fpage>
<lpage>1142</lpage>
<pub-id pub-id-type="doi">10.2174/138161211795656800</pub-id>
<pub-id pub-id-type="pmid">21492090</pub-id>
</element-citation>
</ref>
<ref id="B27-antioxidants-09-00425">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gearhardt</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yokum</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stice</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Brownell</surname>
<given-names>K.D.</given-names>
</name>
</person-group>
<article-title>Relation of obesity to neural activation in response to food commercials</article-title>
<source/>Soc. Cogn. Affect. Neurosci.
          <year>2013</year>
<volume>9</volume>
<fpage>932</fpage>
<lpage>938</lpage>
<pub-id pub-id-type="doi">10.1093/scan/nst059</pub-id>
<pub-id pub-id-type="pmid">23576811</pub-id>
</element-citation>
</ref>
<ref id="B28-antioxidants-09-00425">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alaghband</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Common influences of non-competitive NMDA receptor antagonists on the consolidation and reconsolidation of cocaine-cue memory</article-title>
<source/>Psychopharmacology
          <year>2013</year>
<volume>226</volume>
<fpage>707</fpage>
<lpage>719</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-012-2793-y</pub-id>
<pub-id pub-id-type="pmid">22829432</pub-id>
</element-citation>
</ref>
<ref id="B29-antioxidants-09-00425">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stanley</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Spears</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Dee</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Lateral hypothalamic injections of glutamate, kainic acid,d,l-α-amino-3-hydroxy-5-methyl-isoxazole propionic acid or N-methyl-d-aspartic acid rapidly elicit intense transient eating in rats</article-title>
<source/>Brain Res.
          <year>1993</year>
<volume>613</volume>
<fpage>88</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1016/0006-8993(93)90458-Y</pub-id>
<pub-id pub-id-type="pmid">7688643</pub-id>
</element-citation>
</ref>
<ref id="B30-antioxidants-09-00425">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Spanagel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Krystal</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Glutamatergic targets for new alcohol medications</article-title>
<source/>Psychopharmacology
          <year>2013</year>
<volume>229</volume>
<fpage>539</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-013-3226-2</pub-id>
<pub-id pub-id-type="pmid">23995381</pub-id>
</element-citation>
</ref>
<ref id="B31-antioxidants-09-00425">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunha-Oliveira</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Acute effects of cocaine, morphine and their combination on bioenergetic function and susceptibility to oxidative stress of rat liver mitochondria</article-title>
<source/>Life Sci.
          <year>2013</year>
<volume>92</volume>
<fpage>1157</fpage>
<lpage>1164</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2013.04.016</pub-id>
<pub-id pub-id-type="pmid">23680378</pub-id>
</element-citation>
</ref>
<ref id="B32-antioxidants-09-00425">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunha-Oliveira</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Mitochondrial complex I dysfunction induced by cocaine and cocaine plus morphine in brain and liver mitochondria</article-title>
<source/>Toxicol. Lett.
          <year>2013</year>
<volume>219</volume>
<fpage>298</fpage>
<lpage>306</lpage>
<pub-id pub-id-type="doi">10.1016/j.toxlet.2013.03.025</pub-id>
<pub-id pub-id-type="pmid">23542814</pub-id>
</element-citation>
</ref>
<ref id="B33-antioxidants-09-00425">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pomierny</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Starek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Krzyżanowska</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Starek-Swiechowicz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Smaga</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Pomierny-Chamiolo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Regulska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Budziszewska</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Potential neurotoxic effect of ethylene glycol ethers mixtures</article-title>
<source/>Pharmacol. Rep.
          <year>2013</year>
<volume>65</volume>
<fpage>1415</fpage>
<lpage>1421</lpage>
<pub-id pub-id-type="doi">10.1016/S1734-1140(13)71501-9</pub-id>
<pub-id pub-id-type="pmid">24399739</pub-id>
</element-citation>
</ref>
<ref id="B34-antioxidants-09-00425">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pomierny-Chamiolo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Moniczewski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wydra</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Suder</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Oxidative Stress Biomarkers in Some Rat Brain Structures and Peripheral Organs Underwent Cocaine</article-title>
<source/>Neurotox. Res.
          <year>2013</year>
<volume>23</volume>
<fpage>92</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="doi">10.1007/s12640-012-9335-6</pub-id>
<pub-id pub-id-type="pmid">22791409</pub-id>
</element-citation>
</ref>
<ref id="B35-antioxidants-09-00425">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pomierny-Chamiolo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rup</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pomierny</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Niedzielska-Andres</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kalivas</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Metabotropic glutamatergic receptors and their ligands in drug addiction</article-title>
<source/>Pharmacol. Ther.
          <year>2014</year>
<volume>142</volume>
<fpage>281</fpage>
<lpage>305</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.12.012</pub-id>
<pub-id pub-id-type="pmid">24362085</pub-id>
</element-citation>
</ref>
<ref id="B36-antioxidants-09-00425">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kendler</surname>
<given-names>K.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic Control over mtDNA and Its Relationship to Major Depressive Disorder</article-title>
<source/>Curr. Boil.
          <year>2015</year>
<volume>25</volume>
<fpage>3170</fpage>
<lpage>3177</lpage>
<pub-id pub-id-type="doi">10.1016/j.cub.2015.10.065</pub-id>
<pub-id pub-id-type="pmid">26687620</pub-id>
</element-citation>
</ref>
<ref id="B37-antioxidants-09-00425">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollis</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Van Der Kooij</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Zanoletti</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cantó</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sandi</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Mitochondrial function in the brain links anxiety with social subordination</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2015</year>
<volume>112</volume>
<fpage>15486</fpage>
<lpage>15491</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1512653112</pub-id>
<pub-id pub-id-type="pmid">26621716</pub-id>
</element-citation>
</ref>
<ref id="B38-antioxidants-09-00425">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manji</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Di Prospero</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Ness</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Krams</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Impaired mitochondrial function in psychiatric disorders</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2012</year>
<volume>13</volume>
<fpage>293</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3229</pub-id>
<pub-id pub-id-type="pmid">22510887</pub-id>
</element-citation>
</ref>
<ref id="B39-antioxidants-09-00425">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McManus</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Nasca</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Moffat</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kopinski</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Seifert</surname>
<given-names>E.L.</given-names>
</name>
<name>
<surname>McEwen</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>D.C.</given-names>
</name>
</person-group>
<article-title>Mitochondrial functions modulate neuroendocrine, metabolic, inflammatory, and transcriptional responses to acute psychological stress</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2015</year>
<volume>112</volume>
<fpage>E6614</fpage>
<lpage>E6623</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1515733112</pub-id>
<pub-id pub-id-type="pmid">26627253</pub-id>
</element-citation>
</ref>
<ref id="B40-antioxidants-09-00425">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Purushothaman</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vialou</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Maze</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>N.-Y.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Koo</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic cocaine-regulated epigenomic changes in mouse nucleus accumbens</article-title>
<source/>Genome Boil.
          <year>2014</year>
<volume>15</volume>
<fpage>R65</fpage>
<pub-id pub-id-type="doi">10.1186/gb-2014-15-4-r65</pub-id>
</element-citation>
</ref>
<ref id="B41-antioxidants-09-00425">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergmans</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Mezuk</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Inflammation as a unique marker of suicide ideation distinct from depression syndrome among U.S. adults</article-title>
<source/>J. Affect. Disord.
          <year>2019</year>
<volume>245</volume>
<fpage>1052</fpage>
<lpage>1060</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2018.11.046</pub-id>
<pub-id pub-id-type="pmid">30699847</pub-id>
</element-citation>
</ref>
<ref id="B42-antioxidants-09-00425">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Felger</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Role of Inflammation in Depression and Treatment Implications</article-title>
<source/>Pharmacol. Ther. Cough
          <year>2019</year>
<volume>250</volume>
<fpage>255</fpage>
<lpage>286</lpage>
</element-citation>
</ref>
<ref id="B43-antioxidants-09-00425">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Francija</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Petrovic</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Brkic</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Mitic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Radulovic</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Adzic</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Disruption of the NMDA receptor GluN2A subunit abolishes inflammation-induced depression</article-title>
<source/>Behav. Brain Res.
          <year>2019</year>
<volume>359</volume>
<fpage>550</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2018.10.011</pub-id>
<pub-id pub-id-type="pmid">30296532</pub-id>
</element-citation>
</ref>
<ref id="B44-antioxidants-09-00425">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>González-Parra</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Daudén</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Psoriasis and Depression: The Role of Inflammation</article-title>
<source/>Actas Dermo Sifiliogr.
          <year>2019</year>
<volume>110</volume>
<fpage>12</fpage>
<lpage>19</lpage>
</element-citation>
</ref>
<ref id="B45-antioxidants-09-00425">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konsman</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Inflammation and Depression: A Nervous Plea for Psychiatry to Not Become Immune to Interpretation</article-title>
<source/>Pharmaceuticals
          <year>2019</year>
<volume>12</volume>
<elocation-id>29</elocation-id>
<pub-id pub-id-type="doi">10.3390/ph12010029</pub-id>
<pub-id pub-id-type="pmid">30769887</pub-id>
</element-citation>
</ref>
<ref id="B46-antioxidants-09-00425">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mac Giollabhui</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Swistun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moriarity</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kautz</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Ellman</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Olino</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Abramson</surname>
<given-names>L.Y.</given-names>
</name>
<name>
<surname>Alloy</surname>
<given-names>L.B.</given-names>
</name>
</person-group>
<article-title>Executive dysfunction in depression in adolescence: The role of inflammation and higher body mass</article-title>
<source/>Psychol. Med.
          <year>2019</year>
<volume>50</volume>
<fpage>683</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="doi">10.1017/S0033291719000564</pub-id>
<pub-id pub-id-type="pmid">30919789</pub-id>
</element-citation>
</ref>
<ref id="B47-antioxidants-09-00425">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vengeliene</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cannella</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Spanagel</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Metabolic shift of the kynurenine pathway impairs alcohol and cocaine seeking and relapse</article-title>
<source/>Psychopharmacology
          <year>2016</year>
<volume>233</volume>
<fpage>3449</fpage>
<lpage>3459</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-016-4384-9</pub-id>
<pub-id pub-id-type="pmid">27475106</pub-id>
</element-citation>
</ref>
<ref id="B48-antioxidants-09-00425">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braidy</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brew</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons</article-title>
<source/>Neurotox. Res.
          <year>2009</year>
<volume>16</volume>
<fpage>77</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1007/s12640-009-9051-z</pub-id>
<pub-id pub-id-type="pmid">19526301</pub-id>
</element-citation>
</ref>
<ref id="B49-antioxidants-09-00425">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ting</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Braidy</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Brew</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons</article-title>
<source/>PLoS ONE
          <year>2009</year>
<volume>4</volume>
<elocation-id>e6344</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0006344</pub-id>
<pub-id pub-id-type="pmid">19623258</pub-id>
</element-citation>
</ref>
<ref id="B50-antioxidants-09-00425">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ting</surname>
<given-names>K.K.</given-names>
</name>
<name>
<surname>Brew</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Effect of quinolinic acid on human astrocytes morphology and functions: Implications in Alzheimer’s disease</article-title>
<source/>J. Neuroinflammation
          <year>2009</year>
<volume>6</volume>
<fpage>36</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-6-36</pub-id>
<pub-id pub-id-type="pmid">20003262</pub-id>
</element-citation>
</ref>
<ref id="B51-antioxidants-09-00425">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hodgkins</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Schwarcz</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Interference with cellular energy metabolism reduces kynurenic acid formation in rat brain slices: Reversal by lactate and pyruvate</article-title>
<source/>Eur. J. Neurosci.
          <year>1998</year>
<volume>10</volume>
<fpage>1986</fpage>
<lpage>1994</lpage>
<pub-id pub-id-type="doi">10.1046/j.1460-9568.1998.00208.x</pub-id>
<pub-id pub-id-type="pmid">9753086</pub-id>
</element-citation>
</ref>
<ref id="B52-antioxidants-09-00425">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guillemin</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Pemberton</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Smythe</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Armati</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Brew</surname>
<given-names>B.J.</given-names>
</name>
</person-group>
<article-title>IFN-beta1b induces kynurenine pathway metabolism in human macrophages: Potential implications for multiple sclerosis treatment</article-title>
<source/>J. Interf. Cytokine Res.
          <year>2001</year>
<volume>21</volume>
<fpage>1097</fpage>
<lpage>1101</lpage>
<pub-id pub-id-type="doi">10.1089/107999001317205231</pub-id>
</element-citation>
</ref>
<ref id="B53-antioxidants-09-00425">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Nicolazzo</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Stankovic</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Brew</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer’s Disease Brain</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e59749</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0059749</pub-id>
<pub-id pub-id-type="pmid">23630570</pub-id>
</element-citation>
</ref>
<ref id="B54-antioxidants-09-00425">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braidy</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Clement</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Poljak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sachdev</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes</article-title>
<source/>Antioxid. Redox Signal.
          <year>2019</year>
<volume>30</volume>
<fpage>251</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2017.7269</pub-id>
<pub-id pub-id-type="pmid">29634344</pub-id>
</element-citation>
</ref>
<ref id="B55-antioxidants-09-00425">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adinoff</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Neurobiologic processes in drug reward and addiction</article-title>
<source/>Harv. Rev. Psychiatry
          <year>2004</year>
<volume>12</volume>
<fpage>305</fpage>
<lpage>320</lpage>
<pub-id pub-id-type="doi">10.1080/10673220490910844</pub-id>
<pub-id pub-id-type="pmid">15764467</pub-id>
</element-citation>
</ref>
<ref id="B56-antioxidants-09-00425">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>The dopamine system and alcohol dependence</article-title>
<source/>Shanghai Arch. Psychiatry
          <year>2014</year>
<volume>26</volume>
<fpage>61</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">25092951</pub-id>
</element-citation>
</ref>
<ref id="B57-antioxidants-09-00425">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Biasi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dani</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Reward, addiction, withdrawal to nicotine</article-title>
<source/>Annu. Rev. Neurosci.
          <year>2011</year>
<volume>34</volume>
<fpage>105</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-neuro-061010-113734</pub-id>
<pub-id pub-id-type="pmid">21438686</pub-id>
</element-citation>
</ref>
<ref id="B58-antioxidants-09-00425">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bloomfield</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Ashok</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Volkow</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Howes</surname>
<given-names>O.D.</given-names>
</name>
</person-group>
<article-title>The effects of Delta(9)-tetrahydrocannabinol on the dopamine system</article-title>
<source/>Nature
          <year>2016</year>
<volume>539</volume>
<fpage>369</fpage>
<lpage>377</lpage>
<pub-id pub-id-type="doi">10.1038/nature20153</pub-id>
<pub-id pub-id-type="pmid">27853201</pub-id>
</element-citation>
</ref>
<ref id="B59-antioxidants-09-00425">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Ghrelin, a gastrointestinal hormone, regulates energy balance and lipid metabolism</article-title>
<source/>Biosci. Rep.
          <year>2018</year>
<volume>38</volume>
<pub-id pub-id-type="doi">10.1042/BSR20181061</pub-id>
</element-citation>
</ref>
<ref id="B60-antioxidants-09-00425">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Igarashi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>DiPatrizio</surname>
<given-names>N.V.</given-names>
</name>
<name>
<surname>Narayanaswami</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Piomelli</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Feeding-induced oleoylethanolamide mobilization is disrupted in the gut of diet-induced obese rodents</article-title>
<source/>Biochim. Biophys. Acta
          <year>2015</year>
<volume>1851</volume>
<fpage>1218</fpage>
<lpage>1226</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbalip.2015.05.006</pub-id>
<pub-id pub-id-type="pmid">26024927</pub-id>
</element-citation>
</ref>
<ref id="B61-antioxidants-09-00425">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ochoa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lallès</surname>
<given-names>J.-P.</given-names>
</name>
<name>
<surname>Malbert</surname>
<given-names>C.-H.</given-names>
</name>
<name>
<surname>Val-Laillet</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Dietary sugars: Their detection by the gut-brain axis and their peripheral and central effects in health and diseases</article-title>
<source/>Eur. J. Nutr.
          <year>2015</year>
<volume>54</volume>
<fpage>1</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1007/s00394-014-0776-y</pub-id>
<pub-id pub-id-type="pmid">25296886</pub-id>
</element-citation>
</ref>
<ref id="B62-antioxidants-09-00425">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leong</surname>
<given-names>K.-C.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>King</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Reichel</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Oxytocin and Rodent Models of Addiction</article-title>
<source/>Int. Rev. Neurobiol.
          <year>2018</year>
<volume>140</volume>
<fpage>201</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="pmid">30193705</pub-id>
</element-citation>
</ref>
<ref id="B63-antioxidants-09-00425">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>H.-P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.C.</given-names>
</name>
</person-group>
<article-title>Nonsocial functions of hypothalamic oxytocin</article-title>
<source/>ISRN Neurosci.
          <year>2013</year>
<volume>2013</volume>
<fpage>179272</fpage>
<pub-id pub-id-type="doi">10.1155/2013/179272</pub-id>
<pub-id pub-id-type="pmid">24967304</pub-id>
</element-citation>
</ref>
<ref id="B64-antioxidants-09-00425">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buisman-Pijlman</surname>
<given-names>F.T.A.</given-names>
</name>
<name>
<surname>Sumracki</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Hull</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Tops</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Individual differences underlying susceptibility to addiction: Role for the endogenous oxytocin system</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2014</year>
<volume>119</volume>
<fpage>22</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2013.09.005</pub-id>
<pub-id pub-id-type="pmid">24056025</pub-id>
</element-citation>
</ref>
<ref id="B65-antioxidants-09-00425">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Churchland</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Winkielman</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Modulating social behavior with oxytocin: How does it work? What does it mean?</article-title>
<source/>Horm. Behav.
          <year>2012</year>
<volume>61</volume>
<fpage>392</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="doi">10.1016/j.yhbeh.2011.12.003</pub-id>
<pub-id pub-id-type="pmid">22197271</pub-id>
</element-citation>
</ref>
<ref id="B66-antioxidants-09-00425">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tabbaa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Paedae</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Neuropeptide Regulation of Social Attachment: The Prairie Vole Model</article-title>
<source/>Compr. Physiol.
          <year>2016</year>
<volume>7</volume>
<fpage>81</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="pmid">28135000</pub-id>
</element-citation>
</ref>
<ref id="B67-antioxidants-09-00425">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volkow</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Boyle</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Neuroscience of Addiction: Relevance to Prevention and Treatment</article-title>
<source/>Am. J. Psychiatry
          <year>2018</year>
<volume>175</volume>
<fpage>729</fpage>
<lpage>740</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2018.17101174</pub-id>
<pub-id pub-id-type="pmid">29690790</pub-id>
</element-citation>
</ref>
<ref id="B68-antioxidants-09-00425">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenhill</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Liver: FGF21—The cause of having a ‘sweet tooth’?</article-title>
<source/>Nat. Rev. Endocrinol.
          <year>2017</year>
<volume>13</volume>
<fpage>378</fpage>
<pub-id pub-id-type="doi">10.1038/nrendo.2017.62</pub-id>
<pub-id pub-id-type="pmid">28497814</pub-id>
</element-citation>
</ref>
<ref id="B69-antioxidants-09-00425">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crooks</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Natarajan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>W.-H.</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Elevated FGF21 secretion, PGC-1alpha and ketogenic enzyme expression are hallmarks of iron-sulfur cluster depletion in human skeletal muscle</article-title>
<source/>Hum. Mol. Genet.
          <year>2014</year>
<volume>23</volume>
<fpage>24</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt393</pub-id>
<pub-id pub-id-type="pmid">23943793</pub-id>
</element-citation>
</ref>
<ref id="B70-antioxidants-09-00425">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Domingo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gallego-Escuredo</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Domingo</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>M.D.M.</given-names>
</name>
<name>
<surname>Mateo</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Vidal</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giralt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Villarroya</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients</article-title>
<source/>AIDS
          <year>2010</year>
<volume>24</volume>
<fpage>2629</fpage>
<lpage>2637</lpage>
<pub-id pub-id-type="doi">10.1097/QAD.0b013e3283400088</pub-id>
<pub-id pub-id-type="pmid">20935553</pub-id>
</element-citation>
</ref>
<ref id="B71-antioxidants-09-00425">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guasti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Silvennoinen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bulstrode</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ferretti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sankilampi</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Dunkel</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Elevated FGF21 leads to attenuated postnatal linear growth in preterm infants through GH resistance in chondrocytes</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <year>2014</year>
<volume>99</volume>
<fpage>E2198</fpage>
<lpage>E2206</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2014-1566</pub-id>
<pub-id pub-id-type="pmid">25137423</pub-id>
</element-citation>
</ref>
<ref id="B72-antioxidants-09-00425">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>N.K.-H.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sae-Tan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>A.C.</given-names>
</name>
</person-group>
<article-title>Fibroblast Growth Factor 21 (Fgf21) Gene Expression Is Elevated in the Liver of Mice Fed a High-Carbohydrate Liquid Diet and Attenuated by a Lipid Emulsion but Is Not Upregulated in the Liver of Mice Fed a High-Fat Obesogenic Diet</article-title>
<source/>J. Nutr.
          <year>2016</year>
<volume>146</volume>
<fpage>184</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.3945/jn.115.216572</pub-id>
<pub-id pub-id-type="pmid">26764334</pub-id>
</element-citation>
</ref>
<ref id="B73-antioxidants-09-00425">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrice</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>McIlroy</surname>
<given-names>G.D.</given-names>
</name>
<name>
<surname>Tammireddy</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Reekie</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shearer</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Delibegović</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Whitfield</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Mody</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Elevated Fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid Fenretinide in mice</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>43782</fpage>
<pub-id pub-id-type="doi">10.1038/srep43782</pub-id>
<pub-id pub-id-type="pmid">28256636</pub-id>
</element-citation>
</ref>
<ref id="B74-antioxidants-09-00425">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murakami</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ueba</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shinoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Koga</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kaneda</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hatoko</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yonemitsu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Muro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Oki</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Successful Glycemic Control Decreases the Elevated Serum FGF21 Level without Affecting Normal Serum GDF15 Levels in a Patient with Mitochondrial Diabetes</article-title>
<source/>Tohoku J. Exp. Med.
          <year>2016</year>
<volume>239</volume>
<fpage>89</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1620/tjem.239.89</pub-id>
<pub-id pub-id-type="pmid">27212224</pub-id>
</element-citation>
</ref>
<ref id="B75-antioxidants-09-00425">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoenberg</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Giesy</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Harvatine</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Waldron</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kharitonenkov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boisclair</surname>
<given-names>Y.R.</given-names>
</name>
</person-group>
<article-title>Plasma FGF21 is elevated by the intense lipid mobilization of lactation</article-title>
<source/>Endocrinology
          <year>2011</year>
<volume>152</volume>
<fpage>4652</fpage>
<lpage>4661</lpage>
<pub-id pub-id-type="doi">10.1210/en.2011-1425</pub-id>
<pub-id pub-id-type="pmid">21990311</pub-id>
</element-citation>
</ref>
<ref id="B76-antioxidants-09-00425">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Søberg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sandholt</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Jespersen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Toft</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Von Holstein-Rathlou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grevengoed</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Bredie</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Potthoff</surname>
<given-names>M.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FGF21 Is a Sugar-Induced Hormone Associated with Sweet Intake and Preference in Humans</article-title>
<source/>Cell Metab.
          <year>2017</year>
<volume>25</volume>
<fpage>1045</fpage>
<lpage>1053</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2017.04.009</pub-id>
<pub-id pub-id-type="pmid">28467924</pub-id>
</element-citation>
</ref>
<ref id="B77-antioxidants-09-00425">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Talukdar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>W.T.</given-names>
</name>
<name>
<surname>Paratala</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FGF21 Regulates Sweet and Alcohol Preference</article-title>
<source/>Cell Metab.
          <year>2016</year>
<volume>23</volume>
<fpage>344</fpage>
<lpage>349</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2015.12.008</pub-id>
<pub-id pub-id-type="pmid">26724861</pub-id>
</element-citation>
</ref>
<ref id="B78-antioxidants-09-00425">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Von Holstein-Rathlou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>BonDurant</surname>
<given-names>L.D.</given-names>
</name>
<name>
<surname>Peltekian</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Naber</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Claflin</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Urizar</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Ratner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Holst</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FGF21 Mediates Endocrine Control of Simple Sugar Intake and Sweet Taste Preference by the Liver</article-title>
<source/>Cell Metab.
          <year>2016</year>
<volume>23</volume>
<fpage>335</fpage>
<lpage>343</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2015.12.003</pub-id>
<pub-id pub-id-type="pmid">26724858</pub-id>
</element-citation>
</ref>
<ref id="B79-antioxidants-09-00425">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jimenez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Jambrina</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Casana</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sacristan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Muñoz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Darriba</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rodó</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mallol</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>León</surname>
<given-names>X.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FGF21 gene therapy as treatment for obesity and insulin resistance</article-title>
<source/>EMBO Mol. Med.
          <year>2018</year>
<volume>10</volume>
<fpage>e8791</fpage>
<pub-id pub-id-type="doi">10.15252/emmm.201708791</pub-id>
<pub-id pub-id-type="pmid">29987000</pub-id>
</element-citation>
</ref>
<ref id="B80-antioxidants-09-00425">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Søberg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Dalsgaard</surname>
<given-names>N.B.</given-names>
</name>
<name>
<surname>Jarlhelt</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>N.L.</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vilsbøll</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chenchar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grevengoed</surname>
<given-names>T.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest</article-title>
<source/>Mol. Metab.
          <year>2018</year>
<volume>11</volume>
<fpage>96</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1016/j.molmet.2018.03.010</pub-id>
<pub-id pub-id-type="pmid">29627377</pub-id>
</element-citation>
</ref>
<ref id="B81-antioxidants-09-00425">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freyberg</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Logan</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>The Intertwined Roles of Circadian Rhythms and Neuronal Metabolism Fueling Drug Reward and Addiction</article-title>
<source/>Curr. Opin. Physiol.
          <year>2018</year>
<volume>5</volume>
<fpage>80</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1016/j.cophys.2018.08.004</pub-id>
<pub-id pub-id-type="pmid">30631826</pub-id>
</element-citation>
</ref>
<ref id="B82-antioxidants-09-00425">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Logan</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Hasler</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Forbes</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Franzen</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Torregrossa</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Buysse</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>McClung</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Impact of Sleep and Circadian Rhythms on Addiction Vulnerability in Adolescents</article-title>
<source/>Biol. Psychiatry
          <year>2018</year>
<volume>83</volume>
<fpage>987</fpage>
<lpage>996</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2017.11.035</pub-id>
<pub-id pub-id-type="pmid">29373120</pub-id>
</element-citation>
</ref>
<ref id="B83-antioxidants-09-00425">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Logan</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>W.P.</given-names>
</name>
<name>
<surname>McClung</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Circadian rhythms and addiction: Mechanistic insights and future directions</article-title>
<source/>Behav. Neurosci.
          <year>2014</year>
<volume>128</volume>
<fpage>387</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="doi">10.1037/a0036268</pub-id>
<pub-id pub-id-type="pmid">24731209</pub-id>
</element-citation>
</ref>
<ref id="B84-antioxidants-09-00425">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McClung</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Circadian rhythms, the mesolimbic dopaminergic circuit, and drug addiction</article-title>
<source/>Sci. World J.
          <year>2007</year>
<volume>7</volume>
<fpage>194</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1100/tsw.2007.213</pub-id>
<pub-id pub-id-type="pmid">17982593</pub-id>
</element-citation>
</ref>
<ref id="B85-antioxidants-09-00425">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webb</surname>
<given-names>I.C.</given-names>
</name>
</person-group>
<article-title>Circadian Rhythms and Substance Abuse: Chronobiological Considerations for the Treatment of Addiction</article-title>
<source/>Curr. Psychiatry Rep.
          <year>2017</year>
<volume>19</volume>
<pub-id pub-id-type="doi">10.1007/s11920-017-0764-z</pub-id>
<pub-id pub-id-type="pmid">28188587</pub-id>
</element-citation>
</ref>
<ref id="B86-antioxidants-09-00425">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abarca</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Albrecht</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Spanagel</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Cocaine sensitization and reward are under the influence of circadian genes and rhythm</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2002</year>
<volume>99</volume>
<fpage>9026</fpage>
<lpage>9030</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.142039099</pub-id>
<pub-id pub-id-type="pmid">12084940</pub-id>
</element-citation>
</ref>
<ref id="B87-antioxidants-09-00425">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asher</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schibler</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Crosstalk between components of circadian and metabolic cycles in mammals</article-title>
<source/>Cell Metab.
          <year>2011</year>
<volume>13</volume>
<fpage>125</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2011.01.006</pub-id>
<pub-id pub-id-type="pmid">21284980</pub-id>
</element-citation>
</ref>
<ref id="B88-antioxidants-09-00425">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korshunov</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Blakemore</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Trombley</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Dopamine: A Modulator of Circadian Rhythms in the Central Nervous System</article-title>
<source/>Front. Cell. Neurosci.
          <year>2017</year>
<volume>11</volume>
<fpage>91</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2017.00091</pub-id>
<pub-id pub-id-type="pmid">28420965</pub-id>
</element-citation>
</ref>
<ref id="B89-antioxidants-09-00425">
<label>89.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Zagon</surname>
<given-names>I.S.</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Endogenous Opioids in the Etiology and Treatment of Multiple Sclerosis</article-title>
<source/>Multiple Sclerosis: Perspectives in Treatment and Pathogenesis
          <person-group person-group-type="editor">
<name>
<surname>Zagon</surname>
<given-names>I.S.</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<publisher-name>Codon Publications</publisher-name>
<publisher-loc>Brisbane, Australia</publisher-loc>
<year>2017</year>
</element-citation>
</ref>
<ref id="B90-antioxidants-09-00425">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stephens</surname>
<given-names>M.A.C.</given-names>
</name>
<name>
<surname>Wand</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Stress and the HPA axis: Role of glucocorticoids in alcohol dependence</article-title>
<source/>Alcohol Res.
          <year>2012</year>
<volume>34</volume>
<fpage>468</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="pmid">23584113</pub-id>
</element-citation>
</ref>
<ref id="B91-antioxidants-09-00425">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mysels</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>The relationship between opioid and sugar intake: Review of evidence and clinical applications</article-title>
<source/>J. Opioid Manag.
          <year>2010</year>
<volume>6</volume>
<fpage>445</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="doi">10.5055/jom.2010.0043</pub-id>
<pub-id pub-id-type="pmid">21269006</pub-id>
</element-citation>
</ref>
<ref id="B92-antioxidants-09-00425">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajakumar</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Pellagra in the United States: A historical perspective</article-title>
<source/>South. Med. J.
          <year>2000</year>
<volume>93</volume>
<fpage>272</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="doi">10.1097/00007611-200093030-00005</pub-id>
<pub-id pub-id-type="pmid">10728513</pub-id>
</element-citation>
</ref>
<ref id="B93-antioxidants-09-00425">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bryan</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Mull</surname>
<given-names>S.R.</given-names>
</name>
</person-group>
<article-title>Pellagra Pre-Goldberger: Rupert Blue, Fleming Sandwith, and the “Vitamine Hypothesis”</article-title>
<source/>Trans. Am. Clin. Clim. Assoc.
          <year>2015</year>
<volume>126</volume>
<fpage>20</fpage>
<lpage>45</lpage>
</element-citation>
</ref>
<ref id="B94-antioxidants-09-00425">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirkland</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Translating advances from the basic biology of aging into clinical application</article-title>
<source/>Exp. Gerontol.
          <year>2013</year>
<volume>48</volume>
<fpage>1</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1016/j.exger.2012.11.014</pub-id>
<pub-id pub-id-type="pmid">23237984</pub-id>
</element-citation>
</ref>
<ref id="B95-antioxidants-09-00425">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oldham</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Ivkovic</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Pellagrous encephalopathy presenting as alcohol withdrawal delirium: A case series and literature review</article-title>
<source/>Addict. Sci. Clin. Pract.
          <year>2012</year>
<volume>7</volume>
<fpage>12</fpage>
<pub-id pub-id-type="doi">10.1186/1940-0640-7-12</pub-id>
<pub-id pub-id-type="pmid">23186222</pub-id>
</element-citation>
</ref>
<ref id="B96-antioxidants-09-00425">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jayakumar</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Micheletti</surname>
<given-names>R.G.</given-names>
</name>
</person-group>
<article-title>Joseph Goldberger-Public Health Champion and Investigator of Pellagra</article-title>
<source/>JAMA Dermatol.
          <year>2017</year>
<volume>153</volume>
<fpage>1262</fpage>
<pub-id pub-id-type="doi">10.1001/jamadermatol.2017.4044</pub-id>
<pub-id pub-id-type="pmid">29238837</pub-id>
</element-citation>
</ref>
<ref id="B97-antioxidants-09-00425">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elvehjem</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Madden</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Strong</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Woolley</surname>
<given-names>D.W.</given-names>
</name>
</person-group>
<article-title>The isolation and identification of the anti-black tongue factor. 1937</article-title>
<source/>J. Biol. Chem.
          <year>2002</year>
<volume>277</volume>
<fpage>e22</fpage>
<pub-id pub-id-type="pmid">12243127</pub-id>
</element-citation>
</ref>
<ref id="B98-antioxidants-09-00425">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kohler</surname>
<given-names>R.E.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>The background to Arthur Harden’s discovery of cozymase</article-title>
<source/>Bull. Hist. Med.
          <year>1974</year>
<volume>48</volume>
<fpage>22</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">4370723</pub-id>
</element-citation>
</ref>
<ref id="B99-antioxidants-09-00425">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myrback</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>In memoriam. Hans von Euler-Chelpin</article-title>
<source/>Enzymologia
          <year>1965</year>
<volume>29</volume>
<fpage>105</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="pmid">5327731</pub-id>
</element-citation>
</ref>
<ref id="B100-antioxidants-09-00425">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Otto</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Warburg effect(s)-a biographical sketch of Otto Warburg and his impacts on tumor metabolism</article-title>
<source/>Cancer Metab.
          <year>2016</year>
<volume>4</volume>
<fpage>5</fpage>
<pub-id pub-id-type="doi">10.1186/s40170-016-0145-9</pub-id>
<pub-id pub-id-type="pmid">26962452</pub-id>
</element-citation>
</ref>
<ref id="B101-antioxidants-09-00425">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sauve</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>NAD(+) metabolism: Bioenergetics, signaling and manipulation for therapy</article-title>
<source/>Biochim. Biophys. Acta
          <year>2016</year>
<volume>1864</volume>
<fpage>1787</fpage>
<lpage>1800</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbapap.2016.06.014</pub-id>
<pub-id pub-id-type="pmid">27374990</pub-id>
</element-citation>
</ref>
<ref id="B102-antioxidants-09-00425">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Hollaren</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Diphosphopyridine nucleotide in the prevention, diagnosis and treatment of drug addiction. A preliminary report</article-title>
<source/>West. J. Surg. Obstet. Gynecol.
          <year>1961</year>
<volume>69</volume>
<fpage>213</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="pmid">13730082</pub-id>
</element-citation>
</ref>
<ref id="B103-antioxidants-09-00425">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spaans</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Weusthuis</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Van Der Oost</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kengen</surname>
<given-names>S.W.M.</given-names>
</name>
<name>
<surname>Kengen</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>NADPH-generating systems in bacteria and archaea</article-title>
<source/>Front. Microbiol.
          <year>2015</year>
<volume>6</volume>
<fpage>742</fpage>
<pub-id pub-id-type="doi">10.3389/fmicb.2015.00742</pub-id>
<pub-id pub-id-type="pmid">26284036</pub-id>
</element-citation>
</ref>
<ref id="B104-antioxidants-09-00425">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marohnic</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Bewley</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Engineering and characterization of a NADPH-utilizing cytochrome b5 reductase</article-title>
<source/>Biochemistry
          <year>2003</year>
<volume>42</volume>
<fpage>11170</fpage>
<lpage>11182</lpage>
<pub-id pub-id-type="doi">10.1021/bi034819b</pub-id>
<pub-id pub-id-type="pmid">14503867</pub-id>
</element-citation>
</ref>
<ref id="B105-antioxidants-09-00425">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Htet</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tennyson</surname>
<given-names>A.G.</given-names>
</name>
</person-group>
<article-title>NAD(+) as a Hydride Donor and Reductant</article-title>
<source/>J. Am. Chem. Soc.
          <year>2016</year>
<volume>138</volume>
<fpage>15833</fpage>
<lpage>15836</lpage>
<pub-id pub-id-type="doi">10.1021/jacs.6b10451</pub-id>
<pub-id pub-id-type="pmid">27960347</pub-id>
</element-citation>
</ref>
<ref id="B106-antioxidants-09-00425">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamanna</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Younts</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rosenthal</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The cerebral oxidative metabolic response to acute ethanol administration in rats and cats</article-title>
<source/>Neuropharmacology
          <year>1977</year>
<volume>16</volume>
<fpage>283</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="doi">10.1016/0028-3908(77)90108-3</pub-id>
<pub-id pub-id-type="pmid">558543</pub-id>
</element-citation>
</ref>
<ref id="B107-antioxidants-09-00425">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Keppler</surname>
<given-names>B.K.</given-names>
</name>
<name>
<surname>Wise</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Bent</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>PARP2 Is the Predominant Poly(ADP-Ribose) Polymerase in Arabidopsis DNA Damage and Immune Responses</article-title>
<source/>PLoS Genet.
          <year>2015</year>
<volume>11</volume>
<elocation-id>e1005200</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1005200</pub-id>
<pub-id pub-id-type="pmid">25950582</pub-id>
</element-citation>
</ref>
<ref id="B108-antioxidants-09-00425">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassa</surname>
<given-names>P.O.</given-names>
</name>
<name>
<surname>Haenni</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Elser</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hottiger</surname>
<given-names>M.O.</given-names>
</name>
</person-group>
<article-title>Nuclear ADP-ribosylation reactions in mammalian cells: Where are we today and where are we going?</article-title>
<source/>Microbiol. Mol. Boil. Rev.
          <year>2006</year>
<volume>70</volume>
<fpage>789</fpage>
<lpage>829</lpage>
<pub-id pub-id-type="doi">10.1128/MMBR.00040-05</pub-id>
<pub-id pub-id-type="pmid">16959969</pub-id>
</element-citation>
</ref>
<ref id="B109-antioxidants-09-00425">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abeti</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Duchen</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>Activation of PARP by oxidative stress induced by beta-amyloid: Implications for Alzheimer’s disease</article-title>
<source/>Neurochem. Res.
          <year>2012</year>
<volume>37</volume>
<fpage>2589</fpage>
<lpage>2596</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-012-0895-x</pub-id>
<pub-id pub-id-type="pmid">23076628</pub-id>
</element-citation>
</ref>
<ref id="B110-antioxidants-09-00425">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martire</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fuso</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mosca</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Forte</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Correani</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fontana</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Scarpa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Maras</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>D’Erme</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Bioenergetic Impairment in Animal and Cellular Models of Alzheimer’s Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions</article-title>
<source/>J. Alzheimer’s Dis.
          <year>2016</year>
<volume>54</volume>
<fpage>307</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-151040</pub-id>
<pub-id pub-id-type="pmid">27567805</pub-id>
</element-citation>
</ref>
<ref id="B111-antioxidants-09-00425">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martire</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mosca</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>D’Erme</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>PARP-1 involvement in neurodegeneration: A focus on Alzheimer’s and Parkinson’s diseases</article-title>
<source/>Mech. Ageing Dev.
          <year>2015</year>
<volume>146</volume>
<fpage>53</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1016/j.mad.2015.04.001</pub-id>
<pub-id pub-id-type="pmid">25881554</pub-id>
</element-citation>
</ref>
<ref id="B112-antioxidants-09-00425">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turunc Bayrakdar</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Uyanikgil</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kanit</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Koylu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Yalcin</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Abeta(1-42)-induced rat model of Alzheimer’s disease</article-title>
<source/>Free Radic. Res.
          <year>2014</year>
<volume>48</volume>
<fpage>146</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="doi">10.3109/10715762.2013.857018</pub-id>
<pub-id pub-id-type="pmid">24151909</pub-id>
</element-citation>
</ref>
<ref id="B113-antioxidants-09-00425">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Libien</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shaik</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wolk</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hernández</surname>
<given-names>A.I.</given-names>
</name>
</person-group>
<article-title>Nucleolar PARP-1 Expression Is Decreased in Alzheimer’s Disease: Consequences for Epigenetic Regulation of rDNA and Cognition</article-title>
<source/>Neural Plast.
          <year>2016</year>
<volume>2016</volume>
<fpage>8987928</fpage>
<pub-id pub-id-type="doi">10.1155/2016/8987928</pub-id>
<pub-id pub-id-type="pmid">27034851</pub-id>
</element-citation>
</ref>
<ref id="B114-antioxidants-09-00425">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whitacre</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>N.A.</given-names>
</name>
</person-group>
<article-title>Involvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequences</article-title>
<source/>Cancer Res.
          <year>1995</year>
<volume>55</volume>
<fpage>3697</fpage>
<lpage>3701</lpage>
<pub-id pub-id-type="pmid">7641178</pub-id>
</element-citation>
</ref>
<ref id="B115-antioxidants-09-00425">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Identification of PRKDC (Protein Kinase, DNA-Activated, Catalytic Polypeptide) as an essential gene for colorectal cancer (CRCs) cells</article-title>
<source/>Gene
          <year>2016</year>
<volume>584</volume>
<fpage>90</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2016.03.020</pub-id>
<pub-id pub-id-type="pmid">26992638</pub-id>
</element-citation>
</ref>
<ref id="B116-antioxidants-09-00425">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horenstein</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sizzano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lusso</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Besso</surname>
<given-names>F.G.</given-names>
</name>
<name>
<surname>Ferrero</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Deaglio</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Corno</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Malavasi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus</article-title>
<source/>Mol. Med.
          <year>2009</year>
<volume>15</volume>
<fpage>76</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.2119/molmed.2008.00108</pub-id>
<pub-id pub-id-type="pmid">19052657</pub-id>
</element-citation>
</ref>
<ref id="B117-antioxidants-09-00425">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camacho-Pereira</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tarragó</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Chini</surname>
<given-names>C.C.S.</given-names>
</name>
<name>
<surname>Nin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Escande</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Puranik</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Schoon</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Galina</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism</article-title>
<source/>Fac. Opin.
          <year>2016</year>
<volume>23</volume>
<fpage>1127</fpage>
<lpage>1139</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2016.05.006</pub-id>
<pub-id pub-id-type="pmid">27304511</pub-id>
</element-citation>
</ref>
<ref id="B118-antioxidants-09-00425">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerreiro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Privat</surname>
<given-names>A.-L.</given-names>
</name>
<name>
<surname>Bressac</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Toulorge</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>CD38 in Neurodegeneration and Neuroinflammation</article-title>
<source/>Cells
          <year>2020</year>
<volume>9</volume>
<elocation-id>471</elocation-id>
<pub-id pub-id-type="doi">10.3390/cells9020471</pub-id>
<pub-id pub-id-type="pmid">32085567</pub-id>
</element-citation>
</ref>
<ref id="B119-antioxidants-09-00425">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaquero</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sternglanz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Reinberg</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs</article-title>
<source/>Oncogene
          <year>2007</year>
<volume>26</volume>
<fpage>5505</fpage>
<lpage>5520</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1210617</pub-id>
<pub-id pub-id-type="pmid">17694090</pub-id>
</element-citation>
</ref>
<ref id="B120-antioxidants-09-00425">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Krautkramer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Denu</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Metabolic Regulation of Histone Post-Translational Modifications</article-title>
<source/>ACS Chem. Boil.
          <year>2015</year>
<volume>10</volume>
<fpage>95</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1021/cb500846u</pub-id>
</element-citation>
</ref>
<ref id="B121-antioxidants-09-00425">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braidy</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Poljak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jayasena</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mansour</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chan-Ling</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Smythe</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sachdev</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Differential expression of sirtuins in the aging rat brain</article-title>
<source/>Front. Cell. Neurosci.
          <year>2015</year>
<volume>9</volume>
<fpage>167</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2015.00167</pub-id>
<pub-id pub-id-type="pmid">26005404</pub-id>
</element-citation>
</ref>
<ref id="B122-antioxidants-09-00425">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Satoh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brace</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Rensing</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cliften</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wozniak</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Herzog</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>S.-I.</given-names>
</name>
<name>
<surname>Clifton</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH</article-title>
<source/>Cell Metab.
          <year>2013</year>
<volume>18</volume>
<fpage>416</fpage>
<lpage>430</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2013.07.013</pub-id>
<pub-id pub-id-type="pmid">24011076</pub-id>
</element-citation>
</ref>
<ref id="B123-antioxidants-09-00425">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation</article-title>
<source/>J. Biol. Chem.
          <year>2008</year>
<volume>283</volume>
<fpage>27628</fpage>
<lpage>27635</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M805711200</pub-id>
<pub-id pub-id-type="pmid">18687677</pub-id>
</element-citation>
</ref>
<ref id="B124-antioxidants-09-00425">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothgiesser</surname>
<given-names>K.M.</given-names>
</name>
</person-group>
<article-title>SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310</article-title>
<source/>J. Cell Sci.
          <year>2010</year>
<volume>123</volume>
<fpage>4251</fpage>
<lpage>4258</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.073783</pub-id>
<pub-id pub-id-type="pmid">21081649</pub-id>
</element-citation>
</ref>
<ref id="B125-antioxidants-09-00425">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nogueiras</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Habegger</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Chaudhary</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Finan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Banks</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dietrich</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Sinclair</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pfluger</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Tschöp</surname>
<given-names>M.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sirtuin 1 and sirtuin 3: Physiological modulators of metabolism</article-title>
<source/>Physiol. Rev.
          <year>2012</year>
<volume>92</volume>
<fpage>1479</fpage>
<lpage>1514</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00022.2011</pub-id>
<pub-id pub-id-type="pmid">22811431</pub-id>
</element-citation>
</ref>
<ref id="B126-antioxidants-09-00425">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Mitochondrial PAK6 inhibits prostate cancer cell apoptosis via the PAK6-SIRT4-ANT2 complex</article-title>
<source/>Theranostics
          <year>2020</year>
<volume>10</volume>
<fpage>2571</fpage>
<lpage>2586</lpage>
<pub-id pub-id-type="doi">10.7150/thno.42874</pub-id>
<pub-id pub-id-type="pmid">32194820</pub-id>
</element-citation>
</ref>
<ref id="B127-antioxidants-09-00425">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Sirt5 Attenuates Cisplatin-Induced Acute Kidney Injury through Regulation of Nrf2/HO-1 and Bcl-2</article-title>
<source/>BioMed Res. Int.
          <year>2019</year>
<volume>2019</volume>
<pub-id pub-id-type="doi">10.1155/2019/4745132</pub-id>
<pub-id pub-id-type="pmid">31815138</pub-id>
</element-citation>
</ref>
<ref id="B128-antioxidants-09-00425">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Diecke</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.Y.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mordwinkin</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Chua</surname>
<given-names>K.F.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>The role of SIRT6 protein in aging and reprogramming of human induced pluripotent stem cells</article-title>
<source/>J. Biol. Chem.
          <year>2013</year>
<volume>288</volume>
<fpage>18439</fpage>
<lpage>18447</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.405928</pub-id>
<pub-id pub-id-type="pmid">23653361</pub-id>
</element-citation>
</ref>
<ref id="B129-antioxidants-09-00425">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vazquez</surname>
<given-names>B.N.</given-names>
</name>
<name>
<surname>Thackray</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Serrano</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Sirtuins and DNA damage repair: SIRT7 comes to play</article-title>
<source/>Nucleus
          <year>2017</year>
<volume>8</volume>
<fpage>107</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.1080/19491034.2016.1264552</pub-id>
<pub-id pub-id-type="pmid">28406750</pub-id>
</element-citation>
</ref>
<ref id="B130-antioxidants-09-00425">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Essuman</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Summers</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>DiAntonio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Milbrandt</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The SARM1 Toll/Interleukin-1 Receptor (TIR) Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration</article-title>
<source/>Neuron
          <year>2017</year>
<volume>93</volume>
<fpage>1334</fpage>
<lpage>1343</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2017.02.022</pub-id>
<pub-id pub-id-type="pmid">28334607</pub-id>
</element-citation>
</ref>
<ref id="B131-antioxidants-09-00425">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerdts</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brace</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>DiAntonio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Milbrandt</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>SARM1 activation triggers axon degeneration locally via NAD(+) destruction</article-title>
<source/>Science
          <year>2015</year>
<volume>348</volume>
<fpage>453</fpage>
<lpage>457</lpage>
<pub-id pub-id-type="doi">10.1126/science.1258366</pub-id>
<pub-id pub-id-type="pmid">25908823</pub-id>
</element-citation>
</ref>
<ref id="B132-antioxidants-09-00425">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerdts</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Summers</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Milbrandt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>DiAntonio</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism</article-title>
<source/>Neuron
          <year>2016</year>
<volume>89</volume>
<fpage>449</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2015.12.023</pub-id>
<pub-id pub-id-type="pmid">26844829</pub-id>
</element-citation>
</ref>
<ref id="B133-antioxidants-09-00425">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murata</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Khine</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>K.-I.</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sakaguchi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>c-Jun N-terminal kinase (JNK)-mediated phosphorylation of SARM1 regulates NAD(+) cleavage activity to inhibit mitochondrial respiration</article-title>
<source/>J. Biol. Chem.
          <year>2018</year>
<volume>293</volume>
<fpage>18933</fpage>
<lpage>18943</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.RA118.004578</pub-id>
<pub-id pub-id-type="pmid">30333228</pub-id>
</element-citation>
</ref>
<ref id="B134-antioxidants-09-00425">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>DiAntonio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Milbrandt</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD+ depletion</article-title>
<source/>eLife
          <year>2016</year>
<volume>5</volume>
<fpage>1010</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.19749</pub-id>
<pub-id pub-id-type="pmid">27735788</pub-id>
</element-citation>
</ref>
<ref id="B135-antioxidants-09-00425">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Summers</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>DiAntonio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Milbrandt</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2016</year>
<volume>113</volume>
<fpage>E6271</fpage>
<lpage>E6280</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1601506113</pub-id>
<pub-id pub-id-type="pmid">27671644</pub-id>
</element-citation>
</ref>
<ref id="B136-antioxidants-09-00425">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verdin</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>NAD(+) in aging, metabolism, and neurodegeneration</article-title>
<source/>Science
          <year>2015</year>
<volume>350</volume>
<fpage>1208</fpage>
<lpage>1213</lpage>
<pub-id pub-id-type="doi">10.1126/science.aac4854</pub-id>
<pub-id pub-id-type="pmid">26785480</pub-id>
</element-citation>
</ref>
<ref id="B137-antioxidants-09-00425">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aksoy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Escande</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Benech</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Chini</surname>
<given-names>E.N.</given-names>
</name>
</person-group>
<article-title>Regulation of SIRT 1 mediated NAD dependent deacetylation: A novel role for the multifunctional enzyme CD38</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2006</year>
<volume>349</volume>
<fpage>353</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2006.08.066</pub-id>
<pub-id pub-id-type="pmid">16935261</pub-id>
</element-citation>
</ref>
<ref id="B138-antioxidants-09-00425">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hegedűs</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Boros</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fidrus</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Antal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Juhász</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Janka</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jankó</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Paragh</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Emri</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PARP1 Inhibition Augments UVB-Mediated Mitochondrial Changes—Implications for UV-Induced DNA Repair and Photocarcinogenesis</article-title>
<source/>Cancers
          <year>2019</year>
<volume>12</volume>
<elocation-id>5</elocation-id>
<pub-id pub-id-type="doi">10.3390/cancers12010005</pub-id>
<pub-id pub-id-type="pmid">31861350</pub-id>
</element-citation>
</ref>
<ref id="B139-antioxidants-09-00425">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Little</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Poly(ADP-ribose) Polymerase 1 (PARP1) in Atherosclerosis: From Molecular Mechanisms to Therapeutic Implications</article-title>
<source/>Med. Res. Rev.
          <year>2014</year>
<volume>34</volume>
<fpage>644</fpage>
<lpage>675</lpage>
<pub-id pub-id-type="doi">10.1002/med.21300</pub-id>
<pub-id pub-id-type="pmid">24002940</pub-id>
</element-citation>
</ref>
<ref id="B140-antioxidants-09-00425">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cantó</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Brunyánszki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Szántó</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Houten</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Kiss</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Oudart</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PARP-2 Regulates SIRT1 Expression and Whole-Body Energy Expenditure</article-title>
<source/>Cell Metab.
          <year>2011</year>
<volume>13</volume>
<fpage>450</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2011.03.013</pub-id>
<pub-id pub-id-type="pmid">21459329</pub-id>
</element-citation>
</ref>
<ref id="B141-antioxidants-09-00425">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cantó</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Oudart</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Brunyánszki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kiss</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Houtkooper</surname>
<given-names>R.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation</article-title>
<source/>Cell Metab.
          <year>2011</year>
<volume>13</volume>
<fpage>461</fpage>
<lpage>468</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2011.03.004</pub-id>
<pub-id pub-id-type="pmid">21459330</pub-id>
</element-citation>
</ref>
<ref id="B142-antioxidants-09-00425">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ijichi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ichiyama</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hayaishi</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Studies on the biosynthesis of nicotinamide adenine dinucleotide. 3. Comparative in vivo studies on nicotinic acid, nicotinamide, and quinolinic acid as precursors of nicotinamide adenine dinucleotide</article-title>
<source/>J. Boil. Chem.
          <year>1966</year>
<volume>241</volume>
<fpage>3701</fpage>
<lpage>3707</lpage>
</element-citation>
</ref>
<ref id="B143-antioxidants-09-00425">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Rawling</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Roebuck</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Kirkland</surname>
<given-names>J.B.</given-names>
</name>
</person-group>
<article-title>Large supplements of nicotinic acid and nicotinamide increase tissue NAD+ and poly(ADP-ribose) levels but do not affect diethylnitrosamine-induced altered hepatic foci in Fischer-344 rats</article-title>
<source/>J. Nutr.
          <year>1995</year>
<volume>125</volume>
<fpage>1455</fpage>
<lpage>1461</lpage>
<pub-id pub-id-type="pmid">7782898</pub-id>
</element-citation>
</ref>
<ref id="B144-antioxidants-09-00425">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kimura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bier</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>C.L.</given-names>
</name>
</person-group>
<article-title>Summary of workshop discussions on establishing upper limits for amino acids with specific attention to available data for the essential amino acids leucine and tryptophan</article-title>
<source/>J. Nutr.
          <year>2012</year>
<volume>142</volume>
<fpage>2245S</fpage>
<lpage>2248S</lpage>
<pub-id pub-id-type="doi">10.3945/jn.112.160846</pub-id>
<pub-id pub-id-type="pmid">23077196</pub-id>
</element-citation>
</ref>
<ref id="B145-antioxidants-09-00425">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galassi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Di Stefano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brunetti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Orsomando</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Amici</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ruggieri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Magni</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Characterization of human nicotinate phosphoribosyltransferase: Kinetic studies, structure prediction and functional analysis by site-directed mutagenesis</article-title>
<source/>Biochimie
          <year>2012</year>
<volume>94</volume>
<fpage>300</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="doi">10.1016/j.biochi.2011.06.033</pub-id>
<pub-id pub-id-type="pmid">21742010</pub-id>
</element-citation>
</ref>
<ref id="B146-antioxidants-09-00425">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duarte-Pereira</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pereira-Castro</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Correia</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Neto</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Da Costa</surname>
<given-names>L.T.</given-names>
</name>
<name>
<surname>Amorim</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>1973</fpage>
<lpage>1983</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.6538</pub-id>
<pub-id pub-id-type="pmid">26675378</pub-id>
</element-citation>
</ref>
<ref id="B147-antioxidants-09-00425">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lau</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Niere</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The NMN/NaMN adenylyltransferase (NMNAT) protein family</article-title>
<source/>Front. Biosci.
          <year>2009</year>
<volume>14</volume>
<fpage>410</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.2741/3252</pub-id>
<pub-id pub-id-type="pmid">19273075</pub-id>
</element-citation>
</ref>
<ref id="B148-antioxidants-09-00425">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schweiger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hennig</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lerner</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Niere</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hirsch-Kauffmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Specht</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Weise</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Oei</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Characterization of recombinant human nicotinamide mononucleotide adenylyl transferase (NMNAT), a nuclear enzyme essential for NAD synthesis</article-title>
<source/>FEBS Lett.
          <year>2001</year>
<volume>492</volume>
<fpage>95</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-5793(01)02180-9</pub-id>
<pub-id pub-id-type="pmid">11248244</pub-id>
</element-citation>
</ref>
<ref id="B149-antioxidants-09-00425">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berger</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dahlmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms</article-title>
<source/>J. Biol. Chem.
          <year>2005</year>
<volume>280</volume>
<fpage>36334</fpage>
<lpage>36341</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M508660200</pub-id>
<pub-id pub-id-type="pmid">16118205</pub-id>
</element-citation>
</ref>
<ref id="B150-antioxidants-09-00425">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jayaram</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Kusumanchi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yalowitz</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>NMNAT expression and its relation to NAD metabolism</article-title>
<source/>Curr. Med. Chem.
          <year>2011</year>
<volume>18</volume>
<fpage>1962</fpage>
<lpage>1972</lpage>
<pub-id pub-id-type="doi">10.2174/092986711795590138</pub-id>
<pub-id pub-id-type="pmid">21517776</pub-id>
</element-citation>
</ref>
<ref id="B151-antioxidants-09-00425">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mori</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Amici</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mazzola</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Di Stefano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Conforti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Magni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ruggieri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Raffaelli</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Orsomando</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Metabolic profiling of alternative NAD biosynthetic routes in mouse tissues</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<elocation-id>e113939</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0113939</pub-id>
<pub-id pub-id-type="pmid">25423279</pub-id>
</element-citation>
</ref>
<ref id="B152-antioxidants-09-00425">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hara</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Osago</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tsuchiya</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Elevation of Cellular NAD Levels by Nicotinic Acid and Involvement of Nicotinic Acid Phosphoribosyltransferase in Human Cells</article-title>
<source/>J. Boil. Chem.
          <year>2007</year>
<volume>282</volume>
<fpage>24574</fpage>
<lpage>24582</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M610357200</pub-id>
</element-citation>
</ref>
<ref id="B153-antioxidants-09-00425">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guyton</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Niacin in cardiovascular prevention: Mechanisms, efficacy, and safety</article-title>
<source/>Curr. Opin. Lipidol.
          <year>2007</year>
<volume>18</volume>
<fpage>415</fpage>
<lpage>420</lpage>
<pub-id pub-id-type="doi">10.1097/MOL.0b013e3282364add</pub-id>
<pub-id pub-id-type="pmid">17620858</pub-id>
</element-citation>
</ref>
<ref id="B154-antioxidants-09-00425">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaccari</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Nagamia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thoenes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oguchi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hammoud</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>B.V.</given-names>
</name>
</person-group>
<article-title>Efficacy of controlled-release niacin in treatment of metabolic syndrome: Correlation to surrogate markers of atherosclerosis, vascular reactivity, and inflammation</article-title>
<source/>J. Clin. Lipidol.
          <year>2007</year>
<volume>1</volume>
<fpage>605</fpage>
<lpage>613</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacl.2007.10.002</pub-id>
<pub-id pub-id-type="pmid">21291702</pub-id>
</element-citation>
</ref>
<ref id="B155-antioxidants-09-00425">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grant</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kapoor</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Murine glial cells regenerate NAD, after peroxide-induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates</article-title>
<source/>J. Neurochem.
          <year>1998</year>
<volume>70</volume>
<fpage>1759</fpage>
<lpage>1763</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1998.70041759.x</pub-id>
<pub-id pub-id-type="pmid">9523595</pub-id>
</element-citation>
</ref>
<ref id="B156-antioxidants-09-00425">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soudijn</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>van Wijngaarden</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ijzerman</surname>
<given-names>A.P.</given-names>
</name>
</person-group>
<article-title>Nicotinic acid receptor subtypes and their ligands</article-title>
<source/>Med. Res. Rev.
          <year>2007</year>
<volume>27</volume>
<fpage>417</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="doi">10.1002/med.20102</pub-id>
<pub-id pub-id-type="pmid">17238156</pub-id>
</element-citation>
</ref>
<ref id="B157-antioxidants-09-00425">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.-P.</given-names>
</name>
</person-group>
<article-title>[Research progress on nicotinamide phosphoribosyl transferase involved in aging and age-related diseases]</article-title>
<source/>Zhejiang Da Xue Xue Bao Yi Xue Ban
          <year>2011</year>
<volume>40</volume>
<fpage>680</fpage>
<lpage>684</lpage>
<pub-id pub-id-type="pmid">22190532</pub-id>
</element-citation>
</ref>
<ref id="B158-antioxidants-09-00425">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bender</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Tryptophan and niacin nutrition--is there a problem?</article-title>
<source/>Adv. Exp. Med. Biol.
          <year>1996</year>
<volume>398</volume>
<fpage>565</fpage>
<lpage>569</lpage>
<pub-id pub-id-type="pmid">8906326</pub-id>
</element-citation>
</ref>
<ref id="B159-antioxidants-09-00425">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bogan</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Brenner</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor vitamins in human nutrition</article-title>
<source/>Annu. Rev. Nutr.
          <year>2008</year>
<volume>28</volume>
<fpage>115</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.nutr.28.061807.155443</pub-id>
<pub-id pub-id-type="pmid">18429699</pub-id>
</element-citation>
</ref>
<ref id="B160-antioxidants-09-00425">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ratajczak</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Joffraud</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trammell</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Ras</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Canela</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Boutant</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Redpath</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Migaud</surname>
<given-names>M.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells</article-title>
<source/>Nat. Commun.
          <year>2016</year>
<volume>7</volume>
<fpage>13103</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms13103</pub-id>
<pub-id pub-id-type="pmid">27725675</pub-id>
</element-citation>
</ref>
<ref id="B161-antioxidants-09-00425">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tempel</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Rabeh</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Bogan</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Belenky</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wojcik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Seidle</surname>
<given-names>H.F.</given-names>
</name>
<name>
<surname>Nedyalkova</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sauve</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H.-W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nicotinamide riboside kinase structures reveal new pathways to NAD+</article-title>
<source/>PLoS Biol.
          <year>2007</year>
<volume>5</volume>
<elocation-id>e263</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pbio.0050263</pub-id>
<pub-id pub-id-type="pmid">17914902</pub-id>
</element-citation>
</ref>
<ref id="B162-antioxidants-09-00425">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trammell</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Weidemann</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Redpath</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jaksch</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dellinger</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Abel</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Migaud</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Brenner</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Nicotinamide riboside is uniquely and orally bioavailable in mice and humans</article-title>
<source/>Nat. Commun.
          <year>2016</year>
<volume>7</volume>
<fpage>12948</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms12948</pub-id>
<pub-id pub-id-type="pmid">27721479</pub-id>
</element-citation>
</ref>
<ref id="B163-antioxidants-09-00425">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braidy</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis</article-title>
<source/>Exp. Gerontol.
          <year>2020</year>
<volume>132</volume>
<fpage>110831</fpage>
<pub-id pub-id-type="doi">10.1016/j.exger.2020.110831</pub-id>
<pub-id pub-id-type="pmid">31917996</pub-id>
</element-citation>
</ref>
<ref id="B164-antioxidants-09-00425">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braidy</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Jayasena</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Poljak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sachdev</surname>
<given-names>P.S.</given-names>
</name>
</person-group>
<article-title>Sirtuins in cognitive ageing and Alzheimer’s disease</article-title>
<source/>Curr. Opin. Psychiatry
          <year>2012</year>
<volume>25</volume>
<fpage>226</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="doi">10.1097/YCO.0b013e32835112c1</pub-id>
<pub-id pub-id-type="pmid">22327552</pub-id>
</element-citation>
</ref>
<ref id="B165-antioxidants-09-00425">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samodien</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pheiffer</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mabasa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Erasmus</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Louw</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chellan</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Diet-induced hypothalamic dysfunction and metabolic disease, and the therapeutic potential of polyphenols</article-title>
<source/>Mol. Metab.
          <year>2019</year>
<volume>27</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1016/j.molmet.2019.06.022</pub-id>
<pub-id pub-id-type="pmid">31300352</pub-id>
</element-citation>
</ref>
<ref id="B166-antioxidants-09-00425">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fricker</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>E.L.</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>S.I.</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>The Influence of Nicotinamide on Health and Disease in the Central Nervous System</article-title>
<source/>Int. J. Tryptophan Res.
          <year>2018</year>
<volume>11</volume>
<fpage>1178646918776658</fpage>
<pub-id pub-id-type="doi">10.1177/1178646918776658</pub-id>
<pub-id pub-id-type="pmid">29844677</pub-id>
</element-citation>
</ref>
<ref id="B167-antioxidants-09-00425">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Requardt</surname>
<given-names>R.P.</given-names>
</name>
</person-group>
<article-title>Ca(2)(+) signals of astrocytes are modulated by the NAD(+)/NADH redox state</article-title>
<source/>J. Neurochem.
          <year>2012</year>
<volume>120</volume>
<fpage>1014</fpage>
<lpage>1025</lpage>
<pub-id pub-id-type="pmid">22299833</pub-id>
</element-citation>
</ref>
<ref id="B168-antioxidants-09-00425">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Requardt</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Wilhelm</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Rillich</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Hirrlinger</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The biphasic NAD(P)H fluorescence response of astrocytes to dopamine reflects the metabolic actions of oxidative phosphorylation and glycolysis</article-title>
<source/>J. Neurochem.
          <year>2010</year>
<volume>115</volume>
<fpage>483</fpage>
<lpage>492</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06940.x</pub-id>
<pub-id pub-id-type="pmid">20698931</pub-id>
</element-citation>
</ref>
<ref id="B169-antioxidants-09-00425">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferguson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Koo</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rabkin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Heshmati</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Renthal</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Neve</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>N.-Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Essential role of SIRT1 signaling in the nucleus accumbens in cocaine and morphine action</article-title>
<source/>J. Neurosci.
          <year>2013</year>
<volume>33</volume>
<fpage>16088</fpage>
<lpage>16098</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1284-13.2013</pub-id>
<pub-id pub-id-type="pmid">24107942</pub-id>
</element-citation>
</ref>
<ref id="B170-antioxidants-09-00425">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferguson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>N.-Y.</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Neve</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.-D.</given-names>
</name>
<name>
<surname>Call</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Magazu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>SIRT1-FOXO3a regulate cocaine actions in the nucleus accumbens</article-title>
<source/>J. Neurosci.
          <year>2015</year>
<volume>35</volume>
<fpage>3100</fpage>
<lpage>3111</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4012-14.2015</pub-id>
<pub-id pub-id-type="pmid">25698746</pub-id>
</element-citation>
</ref>
<ref id="B171-antioxidants-09-00425">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lahens</surname>
<given-names>N.F.</given-names>
</name>
<name>
<surname>Ballance</surname>
<given-names>H.I.</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>HogenEsch</surname>
<given-names>J.B.</given-names>
</name>
</person-group>
<article-title>A circadian gene expression atlas in mammals: Implications for biology and medicine</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2014</year>
<volume>111</volume>
<fpage>16219</fpage>
<lpage>16224</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1408886111</pub-id>
<pub-id pub-id-type="pmid">25349387</pub-id>
</element-citation>
</ref>
<ref id="B172-antioxidants-09-00425">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lazaroff</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Patankar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>S.O.</given-names>
</name>
<name>
<surname>Chikaraishi</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>The cyclic AMP response element directs tyrosine hydroxylase expression in catecholaminergic central and peripheral nervous system cell lines from transgenic mice</article-title>
<source/>J. Boil. Chem.
          <year>1995</year>
<volume>270</volume>
<fpage>21579</fpage>
<lpage>21589</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.270.37.21579</pub-id>
</element-citation>
</ref>
<ref id="B173-antioxidants-09-00425">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagatsu</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Tyrosine hydroxylase: Human isoforms, structure and regulation in physiology and pathology</article-title>
<source/>Essays Biochem.
          <year>1995</year>
<volume>30</volume>
<fpage>15</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">8822146</pub-id>
</element-citation>
</ref>
<ref id="B174-antioxidants-09-00425">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozburn</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Falcon</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mukherjee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gillman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arey</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McClung</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>The role of clock in ethanol-related behaviors</article-title>
<source/>Neuropsychopharmacology
          <year>2013</year>
<volume>38</volume>
<fpage>2393</fpage>
<lpage>2400</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2013.138</pub-id>
<pub-id pub-id-type="pmid">23722243</pub-id>
</element-citation>
</ref>
<ref id="B175-antioxidants-09-00425">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McClung</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Sidiropoulou</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vitaterna</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Regulation of dopaminergic transmission and cocaine reward by the Clock gene</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2005</year>
<volume>102</volume>
<fpage>9377</fpage>
<lpage>9381</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0503584102</pub-id>
<pub-id pub-id-type="pmid">15967985</pub-id>
</element-citation>
</ref>
<ref id="B176-antioxidants-09-00425">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Logan</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Parekh</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>G.N.</given-names>
</name>
<name>
<surname>Becker-Krail</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>W.P.</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yoshino</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shelton</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NAD+ cellular redox and SIRT1 regulate the diurnal rhythms of tyrosine hydroxylase and conditioned cocaine reward</article-title>
<source/>Mol. Psychiatry
          <year>2019</year>
<volume>24</volume>
<fpage>1668</fpage>
<lpage>1684</lpage>
<pub-id pub-id-type="doi">10.1038/s41380-018-0061-1</pub-id>
<pub-id pub-id-type="pmid">29728703</pub-id>
</element-citation>
</ref>
<ref id="B177-antioxidants-09-00425">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Q.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nicotinamide phosphoribosyltransferase regulates cocaine reward through Sirtuin 1</article-title>
<source/>Exp. Neurol.
          <year>2018</year>
<volume>307</volume>
<fpage>52</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2018.05.010</pub-id>
<pub-id pub-id-type="pmid">29753648</pub-id>
</element-citation>
</ref>
<ref id="B178-antioxidants-09-00425">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguilar-Arnal</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Katada</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Orozco-Solis</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sassone-Corsi</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>NAD(+)-SIRT1 control of H3K4 trimethylation through circadian deacetylation of MLL1</article-title>
<source/>Nat. Struct. Mol. Boil.
          <year>2015</year>
<volume>22</volume>
<fpage>312</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="doi">10.1038/nsmb.2990</pub-id>
</element-citation>
</ref>
<ref id="B179-antioxidants-09-00425">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Renthal</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Covington</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Maze</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sikder</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Robison</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>LaPlant</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Dietz</surname>
<given-names>D.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide analysis of chromatin regulation by cocaine reveals a role for sirtuins</article-title>
<source/>Neuron
          <year>2009</year>
<volume>62</volume>
<fpage>335</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2009.03.026</pub-id>
<pub-id pub-id-type="pmid">19447090</pub-id>
</element-citation>
</ref>
<ref id="B180-antioxidants-09-00425">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Real</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Simões</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Rial</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cunha</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>S.G.</given-names>
</name>
</person-group>
<article-title>Adenosine A2A receptors modulate the dopamine D2 receptor-mediated inhibition of synaptic transmission in the mouse prefrontal cortex</article-title>
<source/>Eur. J. Neurosci.
          <year>2018</year>
<volume>47</volume>
<fpage>1127</fpage>
<lpage>1134</lpage>
<pub-id pub-id-type="doi">10.1111/ejn.13912</pub-id>
<pub-id pub-id-type="pmid">29570875</pub-id>
</element-citation>
</ref>
<ref id="B181-antioxidants-09-00425">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sichardt</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nieber</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Adenosine A1 receptor: Functional receptor-receptor interactions in the brain</article-title>
<source/>Purinergic Signal.
          <year>2007</year>
<volume>3</volume>
<fpage>285</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.1007/s11302-007-9065-z</pub-id>
<pub-id pub-id-type="pmid">18404442</pub-id>
</element-citation>
</ref>
<ref id="B182-antioxidants-09-00425">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filip</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zaniewska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Frankowska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wydra</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fuxe</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>The importance of the adenosine A(2A) receptor-dopamine D(2) receptor interaction in drug addiction</article-title>
<source/>Curr. Med. Chem.
          <year>2012</year>
<volume>19</volume>
<fpage>317</fpage>
<lpage>355</lpage>
<pub-id pub-id-type="doi">10.2174/092986712803414231</pub-id>
<pub-id pub-id-type="pmid">22335511</pub-id>
</element-citation>
</ref>
<ref id="B183-antioxidants-09-00425">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>H.-B.</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>SIRT2, ERK and Nrf2 Mediate NAD(+) Treatment-Induced Increase in the Antioxidant Capacity of PC12 Cells Under Basal Conditions</article-title>
<source/>Front. Mol. Neurosci.
          <year>2019</year>
<volume>12</volume>
<fpage>108</fpage>
<pub-id pub-id-type="doi">10.3389/fnmol.2019.00108</pub-id>
<pub-id pub-id-type="pmid">31080405</pub-id>
</element-citation>
</ref>
<ref id="B184-antioxidants-09-00425">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fredholm</surname>
<given-names>B.B.</given-names>
</name>
</person-group>
<article-title>Adenosine, an endogenous distress signal, modulates tissue damage and repair</article-title>
<source/>Cell Death Differ.
          <year>2007</year>
<volume>14</volume>
<fpage>1315</fpage>
<lpage>1323</lpage>
<pub-id pub-id-type="doi">10.1038/sj.cdd.4402132</pub-id>
<pub-id pub-id-type="pmid">17396131</pub-id>
</element-citation>
</ref>
<ref id="B185-antioxidants-09-00425">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>H.-B.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Extracellular Degradation Into Adenosine and the Activities of Adenosine Kinase and AMPK Mediate Extracellular NAD(+)-Produced Increases in the Adenylate Pool of BV2 Microglia Under Basal Conditions</article-title>
<source/>Front. Cell. Neurosci.
          <year>2018</year>
<volume>12</volume>
<fpage>343</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2018.00343</pub-id>
<pub-id pub-id-type="pmid">30405351</pub-id>
</element-citation>
</ref>
<ref id="B186-antioxidants-09-00425">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardie</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Keeping the home fires burning: AMP-activated protein kinase</article-title>
<source/>J. R. Soc. Interface
          <year>2018</year>
<volume>15</volume>
<fpage>20170774</fpage>
<pub-id pub-id-type="doi">10.1098/rsif.2017.0774</pub-id>
<pub-id pub-id-type="pmid">29343628</pub-id>
</element-citation>
</ref>
<ref id="B187-antioxidants-09-00425">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>SIRT1 Mediates Apelin-13 in Ameliorating Chronic Normobaric Hypoxia-induced Anxiety-like Behavior by Suppressing NF-kappaB Pathway in Mice Hippocampus</article-title>
<source/>Neuroscience
          <year>2018</year>
<volume>381</volume>
<fpage>22</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2018.04.013</pub-id>
<pub-id pub-id-type="pmid">29680708</pub-id>
</element-citation>
</ref>
<ref id="B188-antioxidants-09-00425">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>Lactobacillus sakei Alleviates High-Fat-Diet-Induced Obesity and Anxiety in Mice by Inducing AMPK Activation and SIRT1 Expression and Inhibiting Gut Microbiota-Mediated NF-kappaB Activation</article-title>
<source/>Mol. Nutr. Food Res.
          <year>2019</year>
<volume>63</volume>
<fpage>e1800978</fpage>
<pub-id pub-id-type="doi">10.1002/mnfr.201800978</pub-id>
<pub-id pub-id-type="pmid">30636176</pub-id>
</element-citation>
</ref>
<ref id="B189-antioxidants-09-00425">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>SIRT1: The Value of Functional Outcome, Stroke-Related Dementia, Anxiety, and Depression in Patients with Acute Ischemic Stroke</article-title>
<source/>J. Stroke Cerebrovasc. Dis.
          <year>2019</year>
<volume>28</volume>
<fpage>205</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2018.09.037</pub-id>
<pub-id pub-id-type="pmid">30361109</pub-id>
</element-citation>
</ref>
<ref id="B190-antioxidants-09-00425">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Libert</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pointer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>E.L.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Asara</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Kapur</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bergmann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Preisig</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Otowa</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SIRT1 activates MAO-A in the brain to mediate anxiety and exploratory drive</article-title>
<source/>Cell
          <year>2011</year>
<volume>147</volume>
<fpage>1459</fpage>
<lpage>1472</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2011.10.054</pub-id>
<pub-id pub-id-type="pmid">22169038</pub-id>
</element-citation>
</ref>
<ref id="B191-antioxidants-09-00425">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Homiack</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Sawyer</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Schrader</surname>
<given-names>L.A.</given-names>
</name>
</person-group>
<article-title>BK channel deacetylation by SIRT1 in dentate gyrus regulates anxiety and response to stress</article-title>
<source/>Commun. Biol.
          <year>2018</year>
<volume>1</volume>
<fpage>82</fpage>
<pub-id pub-id-type="doi">10.1038/s42003-018-0088-5</pub-id>
<pub-id pub-id-type="pmid">30271963</pub-id>
</element-citation>
</ref>
<ref id="B192-antioxidants-09-00425">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantó</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gerhart-Hines</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Feige</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Lagouge</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Noriega</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Milne</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Puigserver</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Auwerx</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Noriega</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity</article-title>
<source/>Nature
          <year>2009</year>
<volume>458</volume>
<fpage>1056</fpage>
<lpage>1060</lpage>
<pub-id pub-id-type="doi">10.1038/nature07813</pub-id>
<pub-id pub-id-type="pmid">19262508</pub-id>
</element-citation>
</ref>
<ref id="B193-antioxidants-09-00425">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chau</surname>
<given-names>M.D.L.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gromada</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2010</year>
<volume>107</volume>
<fpage>12553</fpage>
<lpage>12558</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1006962107</pub-id>
<pub-id pub-id-type="pmid">20616029</pub-id>
</element-citation>
</ref>
<ref id="B194-antioxidants-09-00425">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>SIRT1 and energy metabolism</article-title>
<source/>Acta Biochim. Biophys. Sin.
          <year>2013</year>
<volume>45</volume>
<fpage>51</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1093/abbs/gms108</pub-id>
<pub-id pub-id-type="pmid">23257294</pub-id>
</element-citation>
</ref>
<ref id="B195-antioxidants-09-00425">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliva</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bardag-Gorce</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>S.W.</given-names>
</name>
</person-group>
<article-title>Sirt1 is involved in energy metabolism: The role of chronic ethanol feeding and resveratrol</article-title>
<source/>Exp. Mol. Pathol.
          <year>2008</year>
<volume>85</volume>
<fpage>155</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="doi">10.1016/j.yexmp.2008.08.002</pub-id>
<pub-id pub-id-type="pmid">18793633</pub-id>
</element-citation>
</ref>
<ref id="B196-antioxidants-09-00425">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boily</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Seifert</surname>
<given-names>E.L.</given-names>
</name>
<name>
<surname>Bevilacqua</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X.H.</given-names>
</name>
<name>
<surname>Sabourin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Estey</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Moffat</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saliba</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jardine</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SirT1 regulates energy metabolism and response to caloric restriction in mice</article-title>
<source/>PLoS ONE
          <year>2008</year>
<volume>3</volume>
<elocation-id>e1759</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0001759</pub-id>
<pub-id pub-id-type="pmid">18335035</pub-id>
</element-citation>
</ref>
<ref id="B197-antioxidants-09-00425">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsui</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kohno</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yaku</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Inutsuka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yokota-Hashimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Suga</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuronal SIRT1 regulates macronutrient-based diet selection through FGF21 and oxytocin signalling in mice</article-title>
<source/>Nat. Commun.
          <year>2018</year>
<volume>9</volume>
<fpage>4604</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-018-07033-z</pub-id>
<pub-id pub-id-type="pmid">30389922</pub-id>
</element-citation>
</ref>
<ref id="B198-antioxidants-09-00425">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tezze</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Romanello</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Sandri</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>FGF21 as Modulator of Metabolism in Health and Disease</article-title>
<source/>Front. Physiol.
          <year>2019</year>
<volume>10</volume>
<fpage>419</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2019.00419</pub-id>
<pub-id pub-id-type="pmid">31057418</pub-id>
</element-citation>
</ref>
<ref id="B199-antioxidants-09-00425">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martínez-Garza</surname>
<given-names>Ú.</given-names>
</name>
<name>
<surname>Torres-Oteros</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yarritu-Gallego</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marrero</surname>
<given-names>P.F.</given-names>
</name>
<name>
<surname>Haro</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Relat</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges</article-title>
<source/>Int. J. Mol. Sci.
          <year>2019</year>
<volume>20</volume>
<elocation-id>4692</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms20194692</pub-id>
<pub-id pub-id-type="pmid">31546675</pub-id>
</element-citation>
</ref>
<ref id="B200-antioxidants-09-00425">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lawson</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>The effects of oxytocin on eating behaviour and metabolism in humans</article-title>
<source/>Nat. Rev. Endocrinol.
          <year>2017</year>
<volume>13</volume>
<fpage>700</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="doi">10.1038/nrendo.2017.115</pub-id>
<pub-id pub-id-type="pmid">28960210</pub-id>
</element-citation>
</ref>
<ref id="B201-antioxidants-09-00425">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chini</surname>
<given-names>E.N.</given-names>
</name>
</person-group>
<article-title>CD38 as a regulator of cellular NAD: A novel potential pharmacological target for metabolic conditions</article-title>
<source/>Curr. Pharm. Des.
          <year>2009</year>
<volume>15</volume>
<fpage>57</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.2174/138161209787185788</pub-id>
<pub-id pub-id-type="pmid">19149603</pub-id>
</element-citation>
</ref>
<ref id="B202-antioxidants-09-00425">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higashida</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Munesue</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>CD38 and its role in oxytocin secretion and social behavior</article-title>
<source/>Horm. Behav.
          <year>2012</year>
<volume>61</volume>
<fpage>351</fpage>
<lpage>358</lpage>
<pub-id pub-id-type="doi">10.1016/j.yhbeh.2011.12.011</pub-id>
<pub-id pub-id-type="pmid">22227279</pub-id>
</element-citation>
</ref>
<ref id="B203-antioxidants-09-00425">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higashida</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.-J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>W.-J.</given-names>
</name>
<name>
<surname>Akther</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Higashida</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Minabe</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Munesue</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Social memory, amnesia, and autism: Brain oxytocin secretion is regulated by NAD+ metabolites and single nucleotide polymorphisms of CD38</article-title>
<source/>Neurochem. Int.
          <year>2012</year>
<volume>61</volume>
<fpage>828</fpage>
<lpage>838</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2012.01.030</pub-id>
<pub-id pub-id-type="pmid">22366648</pub-id>
</element-citation>
</ref>
<ref id="B204-antioxidants-09-00425">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chandra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Engeln</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schiefer</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Patton</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Riggs</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>McGlincy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Drp1 Mitochondrial Fission in D1 Neurons Mediates Behavioral and Cellular Plasticity during Early Cocaine Abstinence</article-title>
<source/>Neuron
          <year>2017</year>
<volume>96</volume>
<fpage>1327</fpage>
<lpage>1341</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2017.11.037</pub-id>
<pub-id pub-id-type="pmid">29268097</pub-id>
</element-citation>
</ref>
<ref id="B205-antioxidants-09-00425">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PGC1α pathway</article-title>
<source/>J. Pineal Res.
          <year>2018</year>
<volume>65</volume>
<fpage>e12491</fpage>
<pub-id pub-id-type="doi">10.1111/jpi.12491</pub-id>
<pub-id pub-id-type="pmid">29575122</pub-id>
</element-citation>
</ref>
<ref id="B206-antioxidants-09-00425">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grant</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mestayer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Braidy</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Broom</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome during a 6 Hour Intravenous Infusion of NAD</article-title>
<source/>Front. Aging Neurosci.
          <year>2019</year>
<volume>11</volume>
<fpage>257</fpage>
<pub-id pub-id-type="doi">10.3389/fnagi.2019.00257</pub-id>
<pub-id pub-id-type="pmid">31572171</pub-id>
</element-citation>
</ref>
<ref id="B207-antioxidants-09-00425">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braidy</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Mansour</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chan-Ling</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Poljak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Age related changes in NAD+ metabolism oxidative stress and Sirt1 activity in wistar rats</article-title>
<source/>PLoS ONE
          <year>2011</year>
<volume>6</volume>
<elocation-id>e19194</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0019194</pub-id>
<pub-id pub-id-type="pmid">21541336</pub-id>
</element-citation>
</ref>
<ref id="B208-antioxidants-09-00425">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Clement</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sachdev</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Braidy</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Quantitation of NAD+: Why do we need to measure it?</article-title>
<source/>Biochim. Biophys. Acta Gen. Subj.
          <year>2018</year>
<volume>1862</volume>
<fpage>2527</fpage>
<lpage>2532</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbagen.2018.07.023</pub-id>
<pub-id pub-id-type="pmid">30048742</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="antioxidants-09-00425-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>NAD+ biosynthesis pathways. The kynurenine pathway represents the de novo pathway of NAD+ is synthesis from catabolism of the amino acid tryptophan. NAD+ can also be synthesised via salvage of nicotinamide, nicotinic acid, nicotinic acid riboside and nicotinamide riboside form of vitamin B3. Abbreviations: NR kinase, nicotinamide riboside kinase; NAMPT, nicotinamide phosphoribosyltransferase; NMNAT, nicotinamide mononucleotide adenyltransferase; NAPRT, nicotinic acid phosphoribosyltransferase; PNP, purine nucleoside phosphorylase.</p>
</caption>
<graphic xlink:href="antioxidants-09-00425-g001"></graphic>
</fig>
<fig id="antioxidants-09-00425-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Circadian rhythms are regulated by the availability of NAD+. NAMPT is a SIRT1/CLOCK/BMAL1-regulated circadian gene. SIRT1 and NAMPT and NMNAT form part of a circadian regulatory feedback loop, regulating the availability of NAD+. NAD+ regulates SIRT1, SIRT3 and SIRT6 activities. SIRT1 also regulates CLOCK/BMAL1 expression in the suprachiasmatic nucleus. SIRT6 regulates chromatin recruitment of CLOCK/BMAL1. SIRT3 regulates oxidative phosphorylation and fatty acid oxidation in the mitochondria via circadian deacetylation of mitochondrial enzymes. Abbreviations: NAD+, nicotinamide adenine dinucleotide; NAMPT, nicotinamide phosphoribosyltransferase; NMNAT, nicotinamide mononucleotide adenyltransferase; SIRT, sirtuins.</p>
</caption>
<graphic xlink:href="antioxidants-09-00425-g002"></graphic>
</fig>
<fig id="antioxidants-09-00425-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>NAD+ regulates oxytocin activity via CD38 and cADPR. Social behaviour is regulated by the amount of central OXT released due to NAD-dependent calcium release by CD38 activity and cADPR generation. Abbreviations: NAD+, nicotinamide adenine dinucleotide; NADP, nicotinamide adenine dinucleotide phosphate; CD38, NAD+ glycohydrolase; cADPR, cyclic adenosine diphosphoribose; OXT, oxytocin; NAADP, nicotinic acid adenine dinucleotide phosphate; Ryr, ryanodine receptor.</p>
</caption>
<graphic xlink:href="antioxidants-09-00425-g003"></graphic>
</fig>
<fig id="antioxidants-09-00425-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>NAD+ regulates Drp1 associated in mitochondrial homeostasis. CLOCK/BMAL1 modulated mitochondrial biogenesis and mitophagy via NAD-dependent SIRT1. Deacetylation of the transcription factor PGC1A by SIRT1 regulates mitochondrial biogenesis. Drp1-mediated mitochondrial fission precedes mitophagy leading to formation of fragmented mitochondria that are taken up by autophagosomes. Abbreviations: NAD+, nicotinamide adenine dinucleotide; NAMPT, nicotinamide phosphoribosyltransferase; SIRT1, sirtuin-1; OPA1, mitochondrial dynamin like GTPase; MFN1/2, mitofusin-1/2; FIS1, mitochondrial fission 1 protein; DRP1, dynamin-related protein-1; PINK1, PTEN-induced kinase 1; BNIP1, BCL-2 interacting protein 1; PARKIN, E3 ubiquitin-protein ligase parkin.</p>
</caption>
<graphic xlink:href="antioxidants-09-00425-g004"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>